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Abstract 
Atherosclerosis is a complex inflammatory disease. Atherosclerotic lesions 
are characterized by the accumulation of lipid particles and immune cells in the 
subendothelial space, resulting in the narrowing of the arterial lumen restricting 
blood flow. Endothelial cell activation, upon exposure to oxidized lipids and pro-
inflammatory stimuli, plays an important role in the pathogenesis of 
atherosclerosis. This damage leads to endothelial dysfunction in the vessel wall, 
resulting in the expression of chemotactic factors and adhesion molecules, 
attracting monocytes to migrate into the subendothelial space. Here, they 
differentiate into macrophages and phagocytose the lipids, becoming lipid-laden 
foam cells. A significant factor in the pathogenesis of atherosclerosis is the 
chronic activation of G protein-coupled receptors (GPCR) such as Protease 
activated receptor -1 (PAR-1). GPCRs are the largest family of cell surface 
receptors and are expressed in all vascular cell types. In response to agonists, 
these receptors signal to induce pro-inflammatory genes important to 
atherogenesis via the NF-κB cell signaling pathway. The NF-κB pathway is a 
driving force in the formation and progression of atherosclerotic plaques. 
Activation of the NF-κB pathway leads to nuclear translocation of the NF-κB 
transcription factors (p50 and p65) that are kept inactive in the cytoplasm by 
association with the regulatory protein, IκBα. Activated GPCRs stimulate the IκB 
kinase which phosphorylates IκBα, leading to IκBα ubiquitination and 
xiii 
 
proteasomal degradation. The transcription factors are then released from IκBα, 
allowing them to accumulate in the nucleus. NF-κB transcription factors activate 
the expression of genes for key steps in plaque initiation such as the recruitment 
of monocytes, stimulation of lymphocytes, and the proliferation and migration of 
underlying vascular smooth muscle cells. Utilizing the PAR-1, we establish a 
critical link in GPCR-dependent NF-κB signaling in endothelial dysfunction. This 
involves a three protein complex consisting of CARMA3, a scaffolding protein 
with several protein interaction domains, Bcl10, a linker protein, and MALT1, an 
effector protein that appears to be involved in ubiquitin-mediated activation of the 
IKK complex. The CARMA3/Bcl10/MALT1 complex is a pivotal point in PAR-1 
induced endothelial dysfunction and the disruption of this complex blocks PAR-1 
induced NF-κB signaling and preserves normal endothelial cell function. 
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Chapter I 
 
Thrombin-dependent NF-κB Signaling in Atherosclerosis 
 
Introduction 
Atherosclerosis is an obstruction of the artery’s lumen by the formation of 
plaques composed of lipids, extracellular matrix proteins, immune cells and vascular 
smooth muscle cells which cause the expansion of the vessel wall (1,2). In 2004, 
atherosclerosis and its related diseases, stroke and myocardial infarction, collectively 
referred to as cardiovascular disease, accounted for 31.5% of all female deaths and 
26.8% of all male deaths, making it the most common cause of disease-related deaths in 
the world. Cardiovascular diseases showed the largest gender bias of any disease group 
studied with women being nearly 5% more likely to die from cardiovascular disease and 
the highest geographic presence was in Europe (3).  
The development of plaques occur in the arteries (4). These plaques decrease 
blood flow to the organs, with the heart and brain being particularly affected. The most 
severe health risk is due to the instability of these plaques: rupture can result in a blood 
clot causing stroke or myocardial infarction (1). Plaque formation is a complex process 
involving many molecular influences and the interactions of multiple cell types with the 
endothelial cell layer of the vessel being a key player; for the purposes of this review, we 
will focus on the contributions of endothelial cells and monocytes (5). Atherosclerosis is 
now viewed as chronic inflammation of the vasculature with the transcription factor 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a classic 
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moderator of inflammation, as a potentially major driving force in the disease (Figure 1-
1) (6). Understanding the role of NF-κB will help to better understand the molecular 
mechanisms of atherosclerosis.  
 
Protease Activated Receptor-1 
Protease Activated Receptor-1 (PAR-1) is a member of the G-protein-coupled 
receptor (GPCR) superfamily, which is the largest cell surface receptor family, consisting 
of over 900 known members (7-9). GPCRs are structurally defined by an extracellular N-
terminal tail, seven trans-membrane domains linked together by 6 alternating 
intracellular and extracellular loops and a C-terminal tail (10,11). Members of this 
receptor family respond to a diverse array of ligands such as peptides, amines, 
glycoproteins and enzymes (10). These receptors relay extracellular signals by 
activating multiple intracellular signaling pathways including extracellular signal-
regulated kinases (ERK), Akt, and NF-κB through heterotrimeric G protein-dependent 
and -independent mechanisms and through cross activation of growth factor receptors 
(9,10).  
Both PAR-1 and its agonist thrombin are major participants in endothelial cell 
biology and atherogenesis, affecting cell signaling, gene expression, endothelial 
permeability, angiogenesis and vascular tone (7,8). Thrombin is a protease that binds to 
a hirudin-like domain in the extracellular N-terminus of PAR-1 and cleaves a specific 
sequence exposing the PAR-1 cryptic ligand, SFLLRN-NH2. The newly exposed amino 
acid sequence acts as a tethered ligand binding to the extracellular loop two and 
permanently activating the receptor. This binding causes a conformational change to the 
receptor, revealing the cytoplasmic surfaces to bind to the heterotrimeric G-proteins 
(8,10,12,13). A man-made peptide ligand called SFLLRN, also known as TRAP-6, can 
be used to induce the same response from PAR-1 as thrombin (8,12). 
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Unlike most GPCR ligands which are hormones, PAR-1’s agonist is a serine 
protease, thrombin (10,14). Besides thrombin’s role in the clotting cascade, it is known to 
activate pro-inflammatory responses, especially in endothelial cells which contribute to 
atherogenesis (Figure 1-1) (15). Prothrombin is the inactive precursor of thrombin and is 
produced by the liver or at the site of injury and circulates in the blood. Prothrombin is 
converted to thrombin via cleavage by a complex consisting of tissue factor Xa and 
factor Va, which are normally not present in the vessel, and calcium (16). These tissue 
factors become released into the vessel lumen when the endothelium integrity is 
compromised and can also be expressed by stimulated endothelial cells and leukocytes 
within an atherosclerotic plaque (8,12). Several in vivo studies using mice have pointed 
to a role for thrombin in atherogenesis. A mouse model for atherosclerosis (ApoE-/-) was 
treated with the thrombin inhibitor melagatran, which had a protective effect by reducing 
atherosclerotic plaque size and progression and increasing plaque stability. Using the 
same mouse model, the gene for HCII, a protein inhibitor of thrombin, was knocked out 
and this resulted in significantly increased plaque size (16). This in vivo data indicates a 
potentially significant role for thrombin in atherogenesis in the organism.  
 
Secondary messengers of PAR-1 
Stimulated PAR-1 in the endothelium causes activation of a complex series of 
secondary messengers, leading to multiple responses in the cell. Unstimulated GPCR, 
through its intracellular loops, binds to Gβγ, a heterotrimeric G-protein (guanine 
nucleotide binding protein), which binds to the inactive form of Gα (Gα-GDP). Once a 
ligand binds to a GPCR, the GPCR performs as a guanine nucleotide exchange factor 
(GEF), causing the Gα to exchange the GDP for GTP which releases the Gβγ. Both the 
Gα-GTP and Gβγ are then active until the Gα’s guanosine triphosphatase activity 
hydrolyzes GTP to GDP, allowing it to bind to Gβγ again to block further signaling (17). 
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The activated PAR-1 can couple to several Gα subtypes (Gαq, Gα12/13, Gαi) and the Gβγ 
subunits that act as effectors of multiple cell signaling pathways (8,10,12,13).  
For the purpose of this thesis, we will focus on the role of the Gαq and Gβγ 
subunits, which are essential for PAR-1 induction of the NF-κB signaling pathway and 
expression of cell adhesion molecules (CAM) in endothelial cells (discussed in detail 
below) (18,19). Only a blockade of Gαq, by overexpression of regulator of G protein 
signaling-3T or overexpression of dominant negative mutants of Gαq, inhibits PAR-1 
dependent NF-κB (18). Among the multiple constitutively active G-protein mutants 
transfected into endothelial cells, only Gαq and Gβγ were able to induce NF-κB signaling 
(Figure 1-2) (18).  
Active GTP-Gαq and Gβγ dimers then stimulate phospholipase C-β isozymes 
(PLC-β), a membrane-bound enzyme. PLC-β hydrolyzes phosphatidylinositol 
bisphosphate (PIP2), a membrane phospholipid, to produce inositol trisphosphate (IP3), a 
soluble lipid secondary messenger that spreads throughout the cell and diacylglycerol 
(DAG) which remains membrane-bound (8,17,20,21). DAG acts as a secondary 
messenger along with Ca2+ for stimulation of conventional PKCs (α, β, γ) and as the sole 
secondary messenger for novel PKCs (δ, ε, θ, ή), both activating and localizing the PKC 
to the plasma membrane (19,22). PKC-δ is a primary PKC that regulates PAR-1 
dependent NF-κB transcription in endothelial cells while other PKCs may contribute to 
augmentation of this pathway (Figure 1-2) (19,23-25). 
PAR-1-induced production of IP3 via PLC-β increases intracellular Ca
2+ levels 
(19,26). The increasing IP3 levels activate the IP3-receptors on the endoplasmic 
reticulum, causing the opening of channels that release Ca2+ stores into the cytosol. This 
initial short-lived Ca2+ spike is augmented by the longer lasting Ca2+ influx response in 
which extracellular Ca2+ enters the cell through the transient receptor potential channel 
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1, a cation channel, whose expression is induced in thrombin-dependent NF-κB activity 
(21,26,27).  
Thrombin, by activation of PAR-1, induces release of the Gβγ from the Gαq 
protein, allowing Gβγ to dimerize and recruit phosphatidylinositol 3-kinases (PI3K) to the 
cell membrane to be activated. The active PI3K then goes on to phosphorylate PIP2, 
thereby producing PIP3,
 which serves to recruit PH-domain containing proteins like Akt 
and PDK1 (17). PI3K has been placed as an upstream effector of NF-κB in endothelial 
cells after PAR-1 stimulation while the role of Akt has remained debatable (18,23). 
 
Canonical NF-κB signaling pathway 
Endothelium reacts to injury, infection or other insults by activating an 
inflammatory transcriptional profile releasing growth factors and cytokines and 
expressing cell adhesion molecules (CAMs) to aid in the attraction, binding and 
infiltration of leukocytes (28,29). Thrombin produced at the site of injury induces the 
expression of cytokines such as interleukin 8 (IL-8) and monocyte chemotactic protein-1 
(MCP-1), then CAMs allow leukocytes to adhere to the site of inflammation (15,30). Most 
of these pro-inflammatory mediators are dependent on the NF-κB signaling pathway for 
their expression and can also induce NF-κB signaling (Figure 1-1) (29,30). Cytokines 
produced by the endothelium act in autocrine and paracrine manners to perpetuate the 
initial inflammatory response, partly by a feed-forward mechanism activating the NF-κB 
pathway and furthering atherogenesis (29).  
The canonical NF-κB pathway is traditionally considered to be responsible for 
many of the effects of pro-inflammatory stimulation in the cell. Canonical NF-κB signaling 
can be activated by several different receptor families such as the tumor necrosis factor 
or IL-1 receptor families which, along with GPCR, contribute to atherogenesis primarily 
through activation of the NF-κB pathway (29, 32) (Figure 1-2). This means that receptor-
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proximal events vary by receptor type but all canonical NF-κB signaling eventually 
terminates in the nuclear localization of the NF-κB transcription factors. The point at 
which these diverse receptor signals converge into the common canonical NF-κB 
pathway is at the I kappa B kinase (IKK) complex (31).  
 
The I kappa B kinase complex 
The IKK complex consists of three proteins. IKKγ is the non-catalytic regulator 
protein bound to two serine/threonine kinase sub-units, IKKα and IKKβ (Figure 1-2) 
(31,32). IKKγ is one of the two proteins of the complex required for canonical signaling.  
Ikkγ-/- mice are embryonic lethal at E12.5-E13. The mouse embryonic fibroblasts (MEFs) 
derived from these embryos demonstrate total loss of canonical NF-κB signaling when 
treated with known NF-κB inducers (33). For example, the IL-1 receptor causes 
activation of an E3 ligase, TRAF6, in response to pro-inflammatory stimulation of the cell 
and is a key component of turning these signals into an activated NF-κB pathway. 
TRAF6 causes K63-linked polyubiquitination of IKKγ in a non-degradative fashion that is 
necessary for IKK complex kinase activity and it is thought to assist in the recruitment of 
the IKK kinase. Other receptors capable of inducing NF-κB signaling may use a different 
E3 ligase, such as TRAF2 in the case of TNFR, to perform the same function (Figure 1-
2) (31,34). 
The effector of canonical signaling is the IKKβ subunit. This kinase is responsible 
for the phosphorylation of Inhibitor of κB (IκBα) (Ser32/36) of the IκBα complex (Figure 1-
2) (32,35). Overexpression of IKKβ alone can drive NF-κB signaling in transfected cells 
and Ikkβ-/- mice show an inhibition of canonical IκBα signaling in the fetus (35). IKKβ 
needs to be phosphorylated (Ser177/181) to become fully activated to then phosphorylate 
IκBα (31). The search for an IKK kinase able to phosphorylate IKKβ remains unresolved, 
but of the many kinases proposed, TAK1 now appears to be one of the more likely 
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candidates (31,32). IKKα appears to mainly play a role in non-canonical signaling and is 
not redundant with IKKβ in the cell (review of IKKα see Israel, A., 2010) (31).  
 
IκBα complex and transcription factors of the canonical NF-κB pathway 
 NF-κB transcription factors stand at the ready in the cytoplasm of cells, retained 
there by their regulator protein, IκB (Figure 1-2). IκB binds to the various NF-κB 
transcriptional dimers, inhibiting their ability to bind to target genes by concealing their 
nuclear localization sequence (34). The release of the transcription factors is regulated 
by activation of IKK complex which phosphorylates IκBα (36). This phosphorylation 
results in the recruitment of SCD-βTrCP and UBC4/5, E3 and E2 ligases, respectively, 
which causes K48-linked polyubiquitination at lysines 21 and 22 of IκBα. This leads to 
expedient targeting of IκBα to the proteasome for degradation, which releases the 
transcription factors (34,37).  
 NF-κB transcription factors denote a family of proteins involved in both canonical 
and non-canonical NF-κB signaling. These proteins include p50, p52, p65 (RelA), c-Rel 
and RelB and they share a high degree of homology in their N-termini, called the Rel 
Homology Domain (RHD). The RHD directs the protein’s DNA binding, nuclear 
localization signal, and dimerization properties (38). While these transcription factors can 
form multiple combinations of homo- and heterodimers in terms of canonical NF-κB 
signaling, p65/p65 or p65/p50 dimers are most common (39). Once the transcription 
factors are released, they enter the nucleus and bind to the NF-κB enhancer sequence 
of GGGRNNYYCC, (N= nonspecific base, R=purine, and Y=pyrimidine) where they help 
to form the transcription complex (Figure 1-2) (32,38). NF-κB transcription factors 
regulate the expression of over 100 genes, many of which are pro-inflammatory and pro-
atherogenic, such as cell adhesion molecules and cytokines (38).  
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Immunohistochemistry performed on human atherosclerotic plaques 
demonstrated increased p65 nuclear localization in most of the cell types in the plaque, 
including the endothelial cells, in comparison to almost no NF-κB activity in normal 
tissue. These results were confirmed by electrophoretic mobility shift assay (EMSA) for 
NF-κB activity from nuclear extracts prepared from these plaques (40). Additional in vivo 
evidence for the role of endothelial-specific NF-κB signaling to atherogenesis comes 
from two mouse models. An endothelial-specific Ikkγ-/- mouse was created to disrupt any 
NF-κB signaling in this cell type [41]. These Ikkγ-/- mice were crossed with a mouse 
model of atherosclerosis (ApoE-/-) and fed a high cholesterol diet. After ten weeks on this 
diet, these mice showed a 30% reduction in plaque size, retardation of progression to 
advanced plaques and a 40% reduction of T-cells in the plaque when compared to 
Ikkγ+/+/ApoE-/- mice under the same treatment. To further demonstrate the role of NF-κB 
in the endothelium, an additional transgenic mouse model was created expressing a 
dominant negative IκBα in the endothelium [41]. These mice were once again crossed to 
the ApoE-/- mice and placed on a high cholesterol diet for ten weeks. The IκBα dominant 
negative/ApoE-/- mice showed a 60% reduction in plaque size and a significant reduction 
in plaque progression when compared to ApoE-/- with functional NF-κB signaling in their 
endothelium. The endothelium of the IκBα dominant negative/ApoE-/- mice were also 
almost completely free of most cytokine, chemokine and CAM (VCAM-1, ICAM-1) 
expression (41). Taken together, it appears that the NF-κB pathway, particularly in the 
endothelium, is a major contributor to atherogenesis (Figure 1-1).  
 
The endothelium: a vital component of vascular health 
 A healthy vascular system functions as the efficient network by which the body 
moves nutrients and oxygen into and biological byproducts out of all the body’s tissues 
(42). The endothelium is a flat and unbroken, single-cell-thick, selectively permeable 
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lining of the vessel separating the underlying vascular smooth muscle cells from the 
blood in the vessel lumen (Figure 1-3) (5,43). Endothelial cell layers represent the 
meeting of multiple cell types: the circulating blood cells, endothelium and vascular 
smooth muscle cells. This also places endothelial cells at the center of a diverse array of 
signals to its receptors and in a position prone to overstimulation and dysfunction (Figure 
1-1, 1-3) (44,45). Once thought to be a passive barrier, endothelial cells are now known 
to be at the center of homeostasis in the circulatory system, regulating vascular tone, 
angiogenesis, perfusion, thrombogenesis and inflammatory response (5,45,46). 
Atherogenesis is a slowly developing inflammatory disease with the endothelium at its 
epicenter, and can be separated into several broadly defined stages: endothelial 
dysfunction, fatty streak or plaque initiation, intermediate plaque and, lastly, 
vulnerable/advanced plaque. 
 
Inflammation and endothelial dysfunction 
Endothelial dysfunction and atherosclerosis share many common risk factors 
such as hypercholesterolemia, smoking, hypertension and diabetes. Treatment for 
endothelial dysfunction, like that of atherosclerosis, is to reduce hypertension and lower 
lipid levels, along with diet and exercise (5,45). Endothelial dysfunction is now 
considered the earliest biological condition leading to atherosclerosis and is broadly 
defined as the activation of the endothelium to the harm of the organism (5,47). This 
activation, often attributed to high levels of oxidized low-density lipids (LDL), causes a 
prolonged inflammatory response that significantly alters endothelial function via the 
expression of selectins, CAMs, cytokines, and by altering vascular tone (Figure 1-3) 
(48).  
LDL can rapidly invade through the functional endothelium and become confined 
in the extracellular matrix protein rich space below the endothelium, known as the intima, 
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through association with proteins such as proteoglycans (49). Once deposited, the 
aggregating lipids are oxidized by free radicals or enzymatically modified, releasing 
bioactive phospholipids. These phospholipids can act as ligands for several receptors, 
helping to initiate the inflammatory response (1,50,51). Macrophages that are residing in 
the intima engulf the lipids as part of the innate immune response, but cannot metabolize 
the lipids and become foam cells (44). This model of LDL-induced inflammation of the 
endothelial cell layer has been proven in both in vitro and in vivo models of 
atherosclerosis (Figure 1-1, 1-3) (51).  
Polymorphonuclear neutrophils and leukocytes are attracted to areas of 
inflammation by NF-κB-regulated chemoattractants such as MCP-1 and IL-8 produced 
by the endothelial cells to contribute to atherogensis. Once there, the leukocytes need to 
be honed and retained by the activated endothelial cells to infiltrate through the 
endothelium to the source of inflammation (29,52). This is done through a set of NF-κB 
responsive inflammatory genes known as cell adhesion molecules that facilitate the 
binding between leukocytes and the endothelium. The ability of the dysfunctional 
endothelium to attract leukocytes is a key step early on and throughout atherogenesis 
(Figure 1-3).  
 
Leukocyte adhesion a key result of endothelial dysfunction 
Rolling action is due to a weak tethering of leukocytes to the endothelium by 
selectin glycoproteins on both the leukocytes and endothelial cells (Figure 1-3). 
Leukocytes constitutively express L-selectin (30). The endothelium controls rolling 
through the expression of the L-selectin binding partners, MadCAM-1, Gly-CAM-1 and 
CD-34 and the expression of its own P- and E-selectins in response to inflammatory 
mediators such as thrombin (16,29,30). Thrombin can induce P-selectins which are 
responsible for the early response to inflammation, since they are stored in Weilbel-
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Palade bodies in the endothelial cell and can quickly be moved to the cell surface. At the 
same time, thrombin-dependent NF-κB signaling induces E-selectin transcription and 
translation for the longer lasting late rolling response (16,30). This rolling action by 
leukocytes allows the cell to become further activated by the cytokine-rich environment 
and to firmly adhere to the endothelium (29).  
 
Firm adhesion: the role of ICAM-1 and VCAM-1 
For firm adhesion, the leukocyte integrins CD11a/CD18 and CD11b/CD18 β2 bind 
to members of the immunoglobulin superfamily of adhesion molecules (ICAM-1, VCAM-
1) on the endothelium (Figure 1-3) (29). Under non-inflammatory conditions, ICAM-1 
expression is low on the endothelium surface (30). Pro-inflammatory stimuli such as 
thrombin activation of PAR-1 cause a dramatic increase in ICAM-1 expression on the 
endothelium. This increase in expression level is achieved by an early type I phase and 
slower type II phase induction (53,54). Type I occurs within thirty minutes of stimulation 
of endothelial cells with thrombin and is insensitive to cycloheximide, a protein synthesis 
inhibitor, indicating this early ICAM-1 is kept in an inactive state until thrombin induction 
(53,55).  
The later type II induction is cycloheximide-sensitive and results in an increase in 
ICAM-1 mRNA levels within two hours of thrombin treatment. ICAM-1 protein levels stay 
elevated for twenty-four hours after treatment (54). Type II induction of the ICAM-1 gene 
is dependent on NF-κB signaling in endothelial cells (18,30,56). Disruption of the NF-κB 
pathway downstream of PAR-1 through the use of a chemical inhibitor or the use of RNA 
interference (RNAi) to knock down key proteins in the NF-κB pathway blocks thrombin-
dependent ICAM-1 expression (54,56).  
The ICAM-1 promoter contains four κB enhancer elements at base pair -533 and 
-223 and intronic κB enhancer sites in intron 1 at +70bp and +611bp from the 
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transcriptional start site (54,57). Interestingly, it was discovered that thrombin-dependent 
NF-κB activation of ICAM-1 only required the use of two out of the four possible NF-κB 
binding sites, -233bp and +70 sites. A series of 5’ deletions of the ICAM-1 promoter in a 
reporter construct identified the -233bp κB enhancer site as essential to its 
transcriptional activation. In two separate series of experiments, chromatin 
immunoprecipitation (ChIP) demonstrated the necessity of the +70 site in thrombin-
induced endothelial cell cultures. Both the -233 and +70bp binding sites are needed to 
achieve maximum induction of the ICAM-1 expression in endothelial cells (54,57).  
Using EMSA, thrombin induced protein binding to oligonucleotides based on 
ICAM-1’s NF-κB binding sites. Supershift EMSA were performed to identify the 
combination of NF-κB transcription factors that were binding to the ICAM-1 promoter. 
For both the -233 and +70bp binding sites, the only antibody to produce a supershift was 
the anti-p65 antibody (54,57). Using siRNA to knock down p65 in the cells, both 
thrombin’s and TNFα’s abilities to cause an increase in ICAM-1 protein levels in 
endothelial cells were severely inhibited (57).  
Thrombin-dependent ICAM-1 expression in endothelial cell culture induces the 
adhesion of polymorphonuclear leukocytes, recreating key steps in atherogenesis. This 
response of the endothelium was blocked by pretreating the endothelial cells with an 
ICAM-1 antibody before incubation with the polymorphonuclear leukocytes (54). The NF-
κB pathway is vital for leukocyte/endothelium adhesion and a blockade of NF-κB caused 
a 75% reduction in the number of polymorphonuclear leukocytes that adhered to the 
endothelial cells (54,57). The binding of polymorphonuclear leukocytes to ICAM-1 
causes ICAM-1 to stimulate several cell signaling events leading to gene expression and 
cytoskeletal rearrangements of the endothelial cells that aid in transendothelial migration 
of the leukocytes into intimal space (22). 
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VCAM-1 binds to mononuclear leukocytes, particularly monocytes, for firm 
adhesion. When expressed on the inflamed endothelium, this aids in the transendothelial 
migration of the mononuclear leukocytes into intimal space for plaque development 
(Figure 1-3) (30). Thrombin activation of PAR-1 in endothelial cells mediates an increase 
in VCAM-1 transcription and translation after four hours of treatment (55,58). When 
treated with thrombin or TRAP-6, the endothelial cells caused an ~3.5 fold increase in 
VCAM-1 promoter activity with the use of a reporter construct, and thrombin-induced 
expression of VCAM-1 in endothelial cells is NF-κB dependent (58).  
The VCAM-1 promoter contains two κB enhancer sites at -75 and -65bp from the 
transcriptional start site. When either of these sites in the VCAM-1 promoter reporter 
was mutated, promoter activity was lost (58). Thrombin induction of VCAM-1 
transcription was successfully blocked by the overexpression of a dominant negative 
IκBα or knockdown of the p65 transcription factor in endothelial cells (55). Thrombin only 
induced the binding of p65 to the VCAM-1 promoter-based oligonucleotide as measured 
by supershift EMSA (55,58).  
When endothelial cell cultures were stimulated with thrombin, monocytes 
subsequently added to the culture were able to adhere. This action could be blocked by 
pretreatment with a VCAM-1 antibody but not by an ICAM-1 or E-selectin antibody (55). 
The use of a dominant negative IκBα or knockdown of p65 caused a 73-83% reduction 
in the number of monocytes that were able to bind (55). VCAM-1 is an important 
mediator of plaque formation. Mice were genetically engineered to not express the 4th 
immunoglobulin domain of VCAM-1, which is important to the binding of integrins on the 
monocytes to initiate adhesion. These mice were crossed with the atherosclerosis 
mouse model, ApoE-/-. The decreased expression of VCAM-1 in these mice resulted in 
almost no monocyte adhesion to the endothelium and an 84% reduction in plaque 
formation (59). 
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Fatty streak 
Fatty streak is a waxy yellow deposit in the subendothelial space that is the 
pathological outcome of endothelial dysfunction. The fatty streak is formed by the 
accumulation of lipid-laden macrophage, foam cells, recruited during endothelial 
dysfunction into the intimal space (Figure 1-3). While these fatty streaks are recognized 
as an early step in plaque formation, they have the potential to involute and the negative 
health impact can be averted (49). Foam cells have an active role in plaque progression 
by further feeding the inflammatory response in endothelial cells. This leads to the 
recruitment of even more monocytes by increasing the expression of integrin, adhesion 
molecules and cytokines, and it also drives the maturation of monocytes into 
macrophages (50,51).  
 
Intermediate lesion 
As the plaque progresses, macrophages proliferate and release multiple pro-
inflammatory factors known to mediate NF-κB cell signaling pathways in the surrounding 
cells. The expression of cytokines and CAMs attract T-lymphocytes to the plaque where 
they become T-helper cells. The T-helper cells produce additional cytokines and 
chemokines, attracting even more leukocytes to the maturing plaque (Figure 1-3) 
(49,50).  
Importantly, vascular smooth muscle cells (VSMCs) then start to invade the 
intima in response to increasing concentration of growth factors released from the 
plaque (50,52). VSMCs contribute to plaque size by invasion, proliferation and 
production of extracellular matrix proteins. These extracellular matrix proteins form the 
protective fibrous cap that separates inflammation within the intima and the endothelial 
cell layer (1,49,50). While the plaque is growing, the vessel undergoes compensatory 
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remodeling to try to maintain its lumen size, causing an overall increase in the outside 
diameter of the vessel (49,51). 
 
Advanced / vulnerable lesion 
As the plaque grows, it becomes increasingly less stable and more prone to 
rupture due to a multitude of factors (Figure 1-3). The microvascular outgrowth from the 
vessel wall, which is thought to be promoted by thrombin, contributes to the instability of 
the plaque. These microvessels ease the leukocyte and nutrient entry and cause internal 
hemorrhaging due to the weakness of the vessel. This hemorrhaging then causes local 
increases in thrombin levels, leading to clots and activating the PAR-1 receptor (16,49). 
Foam cells die from their inability to metabolize the oxidized LDL, causing a necrotic 
core within the plaque. The increase of cellular debris and crystalline cholesterol 
continues to bring more leukocytes to weaken the plaque (Figure 1-3) (1,51). The plaque 
is especially unstable where the plaque meets the normal vessel. This frail area is 
known to release pro-thrombogenic material such as tissue factors and stimulate 
thrombus formation in the lumen. This thrombosis can lead to clots and blocked arteries 
and can cause heart attack (1). 
  Rupture also involves the breakdown of the extracellular matrix that makes up 
the protective fibrous cap. Thrombin and other pro-inflammatory factors stimulate 
endothelial cell, T-lymphocyte and macrophage expression of extracellular proteases, 
such as matrix metalloproteinase family members, which break down the fibrous cap 
(1,15,50). T-lymphocytes uniquely contribute to plaque instability via the production of 
IFN-γ which then down regulates VSMC extracellular matrix production (49). Ultimately, 
plaque growth and healing after rupture narrow the vessel lumen to the point at which 
the compensatory remodeling cannot maintain adequate blood flow to the tissue (1,51). 
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Connecting the pieces: CARMA3/Bcl10/MALT1 (CBM) complex in GPCR-
dependent NF-κB signaling 
 CARD-containing MAGUK-1 (CARMA1) is a member of a superfamily of 
scaffolding proteins that use multiple protein interaction domains that gather receptors 
and cytosolic signaling proteins at the cell membrane (Figure 1-4) (60,61). MAGUK 
members contain three defining interaction domains: the PSD-95/Dlg/ZO-1 homologous 
(PDZ) domain, the Src-homology (SH3) domain, and the guanylate kinase (GUK)-like 
domain. CARMA1 is expressed solely in lymphocytes and it diverges from other MAGUK 
proteins by having coiled-coil and caspase recruitment domains (CARD) (Figure 1-5) 
(62).  
In the adaptive immune system, foreign antigens are recognized by lymphocytes 
via the antigen receptors (63). Activated receptors initiate cell signaling through several 
signaling pathways, but stimulation of NF-κB is critical (64). CARMA1 is an 
indispensable component of the antigen-dependent NF-κB signaling pathway in 
lymphocytes (Figure 1-4). This has been demonstrated through the use of multiple 
molecular tools including a dominant negative CARMA1, CARMA1 siRNA knockdown 
and CARMA1-defective T-cell cultures created by chemical mutagenesis, each of which 
resulted in the loss of antigen-dependent NF-κB activity (65-67). Multiple groups have 
generated Carma1-/- mouse strains, which displayed lymphocyte deficiencies associated 
with the loss of antigen-dependent NF-κB signaling (68-71).  
The stimulated T-cell receptor recruits 3-phosphoinositide-dependent kinase 1 
(PDK1) via production of PIP3 at the cell membrane by stimulated PI3K. PDK1 then 
serves to scaffold for both activated PKCθ and CARMA1 (Figure 1-4). The ability of 
PDK1 to interact with CARMA1 characterizes a newly discovered role for this protein 
(72). PDK1 is known to phosphorylate PKC in its activating loop, allowing it to respond to 
Ca2+ and/or DAG (73-75). PDK1 binding to both PKC and CARMA1 allows PKCθ to 
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phosphorylate CARMA1 between the coiled-coil and PDZ domains, resulting in the 
exposure of the CARD domain (76,77). Phosphorylated CARMA1 acts as a molecular 
bridge by recruiting Bcl10, which acts as an adaptor protein to recruit MALT1. MALT1 
recruits the proteins needed to activate the IKK complex (63). Finally, the IKK complex is 
recruited and can thereby be activated by the fully assembled CBM complex to then 
activate the NF-κB signaling pathway (Figure 1-4, 1-5) (78-80). There are notable 
parallels between the antigen- and GPCR-dependent NF-κB signaling pathways. The 
scrutiny of this lymphocyte pathway has provided significant understandings into the 
molecular mechanisms by which thrombin might activate the NF-κB signaling pathway in 
endothelial cells (Figure 1-6).  
 
CARMA3 
 Until recently, GPCR-dependent canonical NF-κB signaling was not fully 
understood. However, GPCR-dependent canonical NF-κB signaling was shown to share 
a number of similarities with antigen receptor-dependent CARMA1/Bcl10/MALT1 
complex-induced canonical NF-κB signaling. The most notable of these similarities is 
that PKC and IKK complex activation are needed for both receptor types (Figure 1-6). 
This led to speculation that CARMA3 might be involved in a GPCR-dependent NF-κB 
signaling pathway in a manner similar to CARMA1 in antigen receptor-dependent NF-κB. 
The innovative work to discover that the CARMA3/Bcl10/MALT1 complex was needed 
for GPCR-induced NF-κB signaling was initially done with angiotensin II type I receptor 
(AGTR1) and lysophosphatidic acid (LPA) receptor (81,82). 
 CARMA3 is a member of the CARMA subfamily of MAGUK proteins (71). 
CARMA1 and CARMA3 proteins are similar with the CARD and the coiled-coil domains 
having 58% and 50% sequence homology, respectively, while the PDZ, SH3 and GUK 
domains share ~20-30% sequence homology (Figure 1-5) (83). The similarities between 
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CARMA3 and CARMA1 are illustrated by the fact that CARMA3 can rescue antigen-
induced NF-κB in CARMA1-deficient T-cells (76). CARMA3 shows an expression pattern 
that is much broader than CARMA1 and is expressed in vascular tissue (62,83,84). 
CARMA3, like CARMA1, functions as a scaffold protein to recruit multiple other proteins 
needed for signaling to the receptor and does not itself have any known transcriptional 
or enzymatic properties (84).  
Overexpression of CARMA3 alone induces canonical NF-κB activity, which is 
blocked by co-expression of a dominant negative IκBα (62,83). Deletion of the CARD 
domain of CARMA3 fully blocked the induction of canonical NF-κB signaling, while 
deletion of PDZ and SH3 only partially blocked the induction. Using a mammalian two-
hybrid screen, it was determined that the CARD domain of CARMA3 specifically 
interacted with the CARD domain of a known NF-κB effector protein, Bcl10 (see below) 
(83). This interaction was confirmed by the ability of CARMA3 to co-immunoprecipitate 
with Bcl10, which could be blocked by the overexpression of either CARD domain 
(Figure 1-5) (83). Overexpression of CARMA3 in Bcl10-/- MEFs blocked CARMA3’s 
ability to induce NF-κB, further showing that CARMA3 and Bcl10 work in the same 
pathway to activate canonical NF-κB signaling (62). 
 PMA/ionomycin treatment of cells is known to activate NF-κB in a PKC- 
dependent manner. When cells over-expressing a dominant negative form of CARMA3 
were treated with PMA/ionomycin, NF-κB induction was blocked. While this did not 
identify the specific PKC involved, it does place PKC upstream of CARMA3 (62). This is 
consistent with data that downstream of the antigen receptor, CARMA1 binds to and is 
phosphorylated by a PKC which results in conformational changes, allowing it to bind to 
Bcl10 and induce canonical NF-κB signaling (84). Further, a point mutation to Ala at 
Ser520 in CARMA3, an area homologous to a PKC phosphorylation site in CARMA1, 
blocked CARMA3-dependent NF-κB activation (76).  
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MEFs derived from Carma3-/- mice were treated with LPA to gauge whether 
canonical NF-κB signaling by this GPCR was affected by the loss of Carma3. Results 
showed that LPA receptor-induced NF-κB transcription factor nuclear localization was 
inhibited in the absence of Carma3 while TNFα-dependent NF-κB signaling remained 
unaffected. Carma3 was also necessary for the LPA-induced phosphorylation of IκBα, 
but interestingly not for the phosphorylation of IKKα/β, thus indicating a possible role for 
a parallel pathway (81).  
In a series of independent experiments performed at the same time, another 
research group explored whether a different GPCR, AGTR1, needed CARMA3 for NF-
κB activation. Using exogenously expressed AGTR1 in cell culture, Ang II-dependent 
NF-κB induction was inhibited by shRNA knockdown or expression of a dominant 
negative mutant of CARMA3 (82). Overexpression of a dominant negative CARMA3 was 
able to block K63-linked polyubiquitination of IKKγ (82). Several PKCs (α, θ, and δ) have 
now been implicated in GPCR CARMA3-dependent canonical NF-κB activation, 
although any direct binding or phosphorylation to CARMA3 remains to be investigated 
(Figure 1-6) (85,86).  
Traditionally, β-arrestin 1 and 2 are known for their role in down regulating 
activated GPCR through endocytosis of the receptor, leading to recycling or degradation. 
Activated GPCRs are phosphorylated by various G-protein receptor kinases (GRKs), 
which then recruit arrestins to the receptors. This helps to uncouple the G-proteins from 
the receptors and assists in receptor internalization through clathrin-coated pits. More 
recently, arrestins have become known to be scaffold proteins that facilitate the 
recruitment and activation of a number of signaling proteins to activated GPCRs (87).  
Recently, β-arrestin 2 has been shown to recruit Carma3 to the LPA receptor 
after stimulation. Knockout MEFs for β-arrestin 1 and β-arrestin 2 showed that a loss of 
β-arrestin 2, but not β-arrestin 1, inhibited NF-κB activation after LPA treatment. β-
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arrestin 2-/- MEFs showed blockade of IκBα phosphorylation and transcription factor 
nuclear localization but no change in IKK phosphorylation, results that are similar to the 
Carma3-/- MEFs (see above). It was then determined that β-arrestin 2 bound to Carma3 
through its CARD domain. In co-immunoprecipitation experiments in transfected 
HEK293T cells, Carma3 could only pull down the LPA receptor when β-arrestin 2 was 
co-transfected to act as a bridge (88).  
 
Bcl10 
B-cell lymphoma/leukemia 10 (Bcl10) is also a scaffold protein that needs to 
oligomerize to activate NF-κB signaling. Bcl10 acts as an adaptor between the upstream 
scaffold protein CARMA3 and MALT1. Unlike CARMA1 or CARMA3, Bcl10 is expressed 
in wide variety of tissues types including both lymphocytes and endothelial cells (82). 
Bcl10 has an N-terminal CARD domain that can bind to CARMA3; this interaction is 
necessary for GPCR-dependent NF-κB signaling along with Bcl10’s Ser/Thr-rich domain 
at the C-terminus (Figure 1-5) (84). Deletion of the CARD domain of either CARMA3 or 
Bcl10 prevents their ability to bind to each other and inhibits CARMA3/Bcl10-dependent 
NF-κB pathway induction (62,83,89). 
  Bcl10 was first described as an oncogene in MALT lymphoma where it is 
overexpressed due to chromosomal translocation, and causes constitutive NF-κB activity 
(90). This can be reproduced in cell culture by overexpression of Bcl10 which activates 
the NF-κB pathway and can be augmented with co-expression of CARMA3 or MALT1 
(62,91). Bcl10, like CARMA3, is necessary for several GPCRs to induce an NF-κB 
response (81,82,86). Bcl10-/- MEFs, when treated with LPA, lose the ability to induce 
canonical phosphorylation of IκBα, similarly to the Carma3-/- MEFs (81). Likewise, 
angiotensin II treatment of cell cultures expressing a dominant negative Bcl10 mutant, or 
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of Bcl10-/- primary hepatocytes, resulted in a loss of Ang II-dependent NF-κB activity 
(82).  
 
MALT1 
 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), 
as the names implies, first came to the attention of researchers as part of an oncogenic 
fusion protein in MALT lymphoma. The t(11;18)(q21;21) chromosomal translocation 
results in the formation of the cIAP2/MALT1 fusion oncoprotein which auto-oligomerizes 
to constitutively stimulate the NF-κB signaling pathway. This fusion oncoprotein leads to 
a treatment-resistant form of MALT lymphoma (90). MALT1 is expressed in a wide 
variety of tissues including lymphocyte and endothelial cells (82).  
Unlike the other members of the CARMA3/Bcl10/MALT1 (CBM) complex, MALT1 
overexpression alone cannot drive canonical NF-κB signaling due to its inability to auto-
oligomerize, but its overexpression can augment the NF-κB signaling by Bcl10 (91). This 
ability to augment increases even more when all three members of the CBM complex 
are overexpressed together (62). Through a series of co-immunoprecipitation 
experiments, it was determined that MALT1’s Ig-like domains were needed to bind to 
regions critical to Bcl10-dependent NF-κB activity (AA 107-119) (Figure 1-5). MALT1 
failed to augment Bcl10-driven NF-κB activity when this twelve amino acid stretch of 
Bcl10 needed to bind to MALT1 was deleted. Binding to Bcl10 initiates MALT1 
oligomerization, which is sufficient for NF-κB signaling (Figure 1-5) (91). 
  
CBM complex and IKK complex 
 Precisely how MALT1 influences the IKK complex to activate NF-κB is still an 
evolving, multi-layered question which has been predominantly explored in the context of 
antigen receptors. Early hints came from working out the interaction between MALT1 
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and Bcl10. Despite its ability to bind to Bcl10, a truncated form of MALT1 missing the C-
terminus beyond the Ig-like domain, was unable to activate the NF-κB pathway, 
demonstrating that the CARMA/Bcl10/MALT1 (CBM) complex is dependent on a fully 
functional MALT1 to activate the NF-κB pathway (91). It now appears that MALT1 serves 
to recruit proteins for the K63-linked polyubiquitination of IKKγ, a necessary step for 
activation of the IKK complex (Figure 1-4, 1-6) (92,93). 
  MALT1 contains two binding sites for TRAF6, an E3 ubiquitin-protein ligase. 
These sites, when mutated, result in a loss of CBM complex-dependent NF-κB signaling. 
TRAF6 binding to MALT1 allows TRAF6 to oligomerize and recruit its ubiquitin 
conjugating enzyme, Ubc13, and its catalytically inactive cofactor, Uev1A, to the CBM 
complex. TRAF6, once bound to MALT1, then causes K63 polyubiquitination of itself, 
MALT1and Bcl10 (94,95). Point mutations of the eleven C-terminal lysines to arginine 
showed a nearly complete loss of ubiquitination of MALT1 and an ~80% fold reduction in 
CBM-dependent NF-κB activity. This was despite the ability of the CBM complex to still 
form in response to stimulation and recruit TRAF6 (92). Similarly, Traf6-/- MEFs that were 
treated with LPA were unable to activate the NF-κB pathway as was seen in LPA treated 
β-arrestin 2-/-, CARMA3-/- and Bcl10-/- MEFs (81).  
IKKγ contains a ubiquitin binding domain that preferably binds K63 ubiquitination 
like that produced by active TRAF6 (96). This domain allows IKKγ to be recruited to the 
CBM complex in response to cellular stimuli through the ubiquitination chains on MALT1 
that are necessary for NF-κB activation. A point mutation in the ubiquitin binding domain 
of IKKγ severely reduces its ability to bind to MALT1 and blocks the ability of the CBM 
complex to cause the degradation of IκBα (92). Lastly, once IKKγ is recruited to the CBM 
complex, TRAF6 then ubiquitinates IKKγ, which is needed for activation of the IKK 
complex to phosphorylate the IκBα complex (Figure 1-4, 1-6) (95). The dependence of 
GPCRs on the formation of the CBM complex for the activation of the NF-κB pathway 
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positions CARMA3, Bcl10 and MALT1 as critical mediators of endothelial dysfunction 
and atherosclerosis.  
 
Conclusion 
Cardiovascular disease stands as a pressing health issue to the world. It is a 
complex and slowly progressing disease that is often associated with a chronic 
inflammatory response to oxidized LDL by multiple cells in the vessel wall. Given the 
endothelium’s position in the vessel, its functional health has a great effect on the 
initiation and progression of atherosclerotic plaques. The NF-κB signaling pathway in 
endothelial cells appears to underlie much of the endothelial dysfunction that occurs in 
atherosclerosis. PAR-1, a GPCR, is known to activate, through an unclear mechanism, 
NF-κB in endothelial cells and inhibition of its antagonist thrombin has benefits in in vivo 
studies of atherosclerosis. The CARMA3/BCL10/MALT1 signaling complex is known to 
activate NF-κB signaling downstream of several GPCRs, making it a possible culprit in 
thrombin-induced endothelial dysfunction.  
 
 
 
 
 
 
 
 
  
. 
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Figure 1-1. The role of endothelial dysfunction in plaque formation is a complex 
process involving many molecular influences and the interactions of multiple 
cell types. Atherosclerosis is a chronic inflammation of the vasculature with the 
transcription factor NF-κB as a major driving force in the disease. Endothelial 
dysfunction is the earliest biological condition leading to atherosclerosis and is 
broadly defined as the stimulation of the endothelium to the detriment of the 
organism. The stimulation of high levels of oxidized low-density lipids causes a 
sustained inflammatory response that significantly alters endothelial function via the 
expression of selectins, lectin-type oxidized LDL receptor 1 (LOX-1), CAMs, and 
cytokines as well as by altering vascular tone. LDL can rapidly invade through the 
functional endothelium and become restricted in the extracellular matrix protein rich 
space beneath the endothelium, known as the intima, through association with 
proteins such as proteoglycans. Once deposited, the aggregating lipids are oxidized 
by free radicals releasing bioactive phospholipids. Macrophages that are residing in 
the intima consume the lipids as part of the innate immune response, but cannot 
metabolize the lipids and become foam cells. 
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Figure 1-2. The canonical NF-κB pathway is activated by multiple receptor 
families and is responsible for many of the effects of pro-inflammatory 
stimulation in the cell. Canonical NF-κB signaling can be activated by several 
different receptor families such as the tumor necrosis factor receptor family. This 
means that receptor-proximal events vary by receptor type but all converge at the IKK 
complex. IKKγ is the non-catalytic regulator protein bound to two kinase sub-units, 
IKKα and IKKβ. IKKγ is one of the two proteins of the complex required for canonical 
signaling. The effector of canonical signaling is the IKKβ subunit, and is responsible 
for the phosphorylation of the IκBα complex. IKKβ needs to be phosphorylated to 
become fully activated to then phosphorylate IκBα. This phosphorylation results in the 
recruitment of ligases that are required for polyubiquitination of the IκBα. This leads to 
expedient targeting of IκBα to the proteasome for degradation, which releases the 
transcription factors p50 and p65 to the nucleus. 
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Figure 1-3. The role of the endothelium through the stages of plaque formation. 
It should be noted that while endothelial dysfunction is the first stage of plaque 
formation, it continues through all other stages as well. See text for a detailed 
description of each stage. This figure is modified from Sanz, J. & Z. A. Fayad, 2008. 
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Figure 1-4. T-cell receptor signals through CARMA1/Bcl10/MALT1 complex for 
the activation of the NF-κB pathway. In the adaptive immune system, foreign 
antigens are recognized by lymphocytes via the T-cell receptors. CARMA1 is a 
necessary component of the antigen-dependent NF-κB signaling pathway in 
lymphocytes. The stimulated T-cell receptor recruits PDK1 via production of PIP3 at 
the cell membrane by activation of PI3K. PDK1 then serves to scaffold for both 
activated PKCθ and CARMA1. PDK1 is known to phosphorylate PKC in its activating 
loop, allowing it to respond to Ca2+ and/or DAG. PDK1 binding to both PKC and 
CARMA1 allows PKCθ to phosphorylate CARMA1 between the coiled-coil and PDZ 
domains, resulting in the exposure of the CARD domain. Phosphorylated CARMA1 
acts as a molecular bridge by recruiting Bcl10, which acts as an adaptor protein to 
recruit MALT1. MALT1 recruits other proteins needed to activate the IKK complex to 
the immunological synapse. The IKK complex is recruited and can thereby be 
induced by the fully assembled CBM complex to activate the NF-κB signaling 
pathway. For an review of CARMA1 in CBM complex signaling, please see Rawlings, 
D.J. and et al. 2006. 
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Figure 1-5.The protein-protein interactions of CBM complex-dependent NF-κB 
activation. CARMA1 and CARMA3 (collectedly referred to as CARMA) is a member 
of a superfamily of scaffolding proteins that use multiple protein interaction domains 
that gather receptors and cytosolic signaling proteins at the cell membrane. MAGUK 
members contain three defining interaction domains: the PSD-95/Dlg/ZO-1 
homologous (PDZ) domain, the Src-homology (SH3) domain, and the guanylate 
kinase (GUK)-like domain. Bcl10 is also a scaffold protein that needs to oligomerize 
to activate NF-κB signaling. Bcl10 acts as an adaptor between the upstream scaffold 
protein CARMA and MALT1. Bcl10 has an N-terminus CARD domain that can bind to 
CARMA; this interaction is necessary for cell receptor-dependent NF-κB signaling 
along with Bcl10’s Ser/Thr-rich domain at the C-terminus. MALT1’s Ig-like domains 
are needed to bind to regions critical to Bcl10-dependent NF-κB activity (AA107-119). 
MALT1 serves to recruit the proteins necessary for NF-κB signaling. This figure is 
modified from Lucas, P. et al., 2004. 
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Figure 1-6. A comparison between T-cell receptor/CBM complex activation 
versus GPCR/CBM complex activation. Until recently, GPCR-dependent canonical 
NF-κB signaling was not fully understood. However, GPCR-dependent canonical NF-
κB signaling was shown to share a number of similarities with antigen receptor-
dependent CARMA1/Bcl10/MALT1 complex-induced canonical NF-κB signaling. The 
most notable of these similarities is that PKC and IKK complex activation are needed 
for both receptor types. This led to speculation that the CBM complex might be 
involved in GPCR-dependent NF-κB signaling.  
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Chapter II 
 
Thrombin-dependent NF-κB Activation and Monocyte/Endothelial Adhesion are 
Mediated by the CARMA3/Bcl10/MALT1 Complex 
 
Abstract 
Thrombin is a potent modulator of endothelial function, and through stimulation of 
NF-κB, induces endothelial expression of ICAM-1 and VCAM-1. These cell-surface 
adhesion molecules recruit inflammatory cells to the vessel wall and thereby participate 
in the development of atherosclerosis, which is increasingly recognized as an 
inflammatory condition. The principal receptor for thrombin on endothelial cells is PAR-1, 
a member of the GPCR superfamily. While it is known that PAR-1 signaling to NF-κB 
depends on initial PKC activation, the subsequent steps leading to stimulation of the 
canonical NF-κB machinery have remained unclear. Here, we demonstrate that a 
complex of proteins containing CARMA3, Bcl10, and MALT1 links PAR-1 activation to 
stimulation of the IKK complex. IKK in turn phosphorylates IκBα, leading to its 
degradation and the release of active NF-κB. Further, we find that although this 
CARMA3/Bcl10/MALT1 complex shares features with a CARMA1-containing complex 
found in lymphocytes, there are significant differences in how the complexes 
communicate with their cognate receptors. Specifically, while the CARMA1-containing 
lymphocyte complex relies on PDK1 for assembly and activation, the CARMA3-
containing endothelial complex functions completely independent of PDK1, and instead 
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relies on β-arrestin 2 for assembly. Finally, we show that thrombin-dependent adhesion 
of monocytes to endothelial cells requires an intact endothelial CARMA3/Bcl10/MALT1 
complex, underscoring the importance of the complex in mediating one of the most 
significant pro-atherogenic effects of thrombin. 
 
Introduction 
Thrombin is a serine protease produced during intravascular coagulation, typically 
as a consequence of vascular injury (1). While thrombin plays a central role in furthering 
the coagulation cascade by cleaving fibrinogen to produce fibrin, it also possesses the 
ability to act like a traditional hormone and elicit responses in a variety of cell types, 
including circulating platelets and endothelial cells (1). These cellular responses are 
mediated by a small family of GPCRs that are activated by thrombin through an unusual 
mechanism. Specifically, thrombin-dependent cleavage removes a target receptor’s N-
terminal sequence, unmasking a cryptic peptide ligand that is present within the 
extracellular domain of the receptor itself. This tethered ligand is then able to interact 
with the ligand-binding pocket of the receptor to stimulate intracellular signaling (1). As a 
result, the family of receptors that are activated in this manner have been termed 
protease-activated receptors, or PARs. Currently, four members of the family have been 
identified, PAR-1 through PAR-4, although not all are directly acted upon by thrombin 
and instead represent targets of other proteases such as trypsin (2-5).  
Because thrombin is short-lived in the circulation, most of its effects are exerted 
locally, near its site of generation. Consequently, endothelial cells adjacent to a site of 
tissue injury and coagulation represent a particularly important target of thrombin action. 
The predominant receptor for thrombin on endothelial cells appears to be PAR-1 (6), and 
while many specific endothelial responses follow stimulation of PAR-1, most can be 
characterized as contributing to “endothelial dysfunction” (7,8). This is defined as a 
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breakdown in the ability of the endothelium to maintain appropriate vascular tone, 
permeability, metabolism, and production of biologically active substances (9). Central to 
the phenomenon of endothelial dysfunction is the expression of adhesion molecules for 
recruitment of inflammatory cells, and the production of pro-inflammatory chemokines 
and cytokines. All of these effects are key to the pathogenesis of atherosclerosis, in 
which early vascular injury due to cholesterol deposition leads to thrombin-induced 
inflammation and propagation of vessel damage.  
Activation of the NF-κB transcription factor represents one of the foremost 
mechanisms responsible for thrombin-induced endothelial dysfunction. As for many 
activators of NF-κB, this occurs through the so-called canonical pathway, whereby 
activation depends upon stimulation of the IKK complex (10-19). IKK in turn directs the 
phosphorylation and subsequent degradation of IκBα, a protein that sequesters NF-κB 
(particularly in the form of RelA/p65) in the cytoplasm (20,21). Upon IκBα degradation, 
NF-κB is then free to translocate to the nucleus and stimulate transcription of various 
pro-inflammatory genes. 
While considerable work has been carried out to demonstrate that thrombin 
induction of the canonical NF-κB pathway in endothelial cells requires prior stimulation of 
PKCδ (2,18,22-24), the molecular links between PKC and the IKK complex have 
remained unclear. Recently, we and others demonstrated that a signaling complex 
composed of a scaffolding protein (CARMA3), a linker protein (Bcl10), and an effector 
protein (MALT1) mediates IKK complex activation, and subsequent NF-κB stimulation, 
downstream of a small number of GPCRs (25-33). Much of our understanding of the 
complex, now referred to as the CBM complex, comes from earlier work in lymphocytes 
where an analogous complex containing the related CARMA1 protein mediates NF-κB 
activation downstream of the antigen receptor (34-37). In the case of lymphocytes, 
antigen stimulation leads to activation of PKC which in turn phosphorylates CARMA1, 
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causing a conformational change that exposes the CARMA1 caspase recruitment 
domain (CARD), a region responsible for binding Bcl10 (38,39). MALT1 is then recruited 
and the intact complex interacts with, and stimulates, the IKK complex. 
Since thrombin-dependent NF-κB activation clearly requires PKC activation as an 
upstream event, we asked whether the CBM complex might function as an integral 
component of the thrombin-responsive signaling machinery. Here we show that all three 
proteins, CARMA3, Bcl10, and MALT1 are essential for thrombin to effectively stimulate 
the canonical NF-κB pathway in endothelial cells. Importantly, we also show that 
disrupting the CBM complex in endothelial cells has important pathophysiologic 
consequences, since it effectively blocks the ability of thrombin to induce expression of 
the adhesion molecules ICAM-1 and VCAM-1, and reduces the thrombin-dependent 
adhesion of monocytes to these endothelial cells. As such, the thrombin receptor now 
joins a small number of GPCRs that utilize the CBM complex to signal to NF-κB. Several 
of these GPCRs share the property of causing endothelial dysfunction and vascular 
inflammation in the context of atherosclerosis. As a result, the CBM complex can be 
seen as an increasingly attractive target for pharmaceutical intervention in our attempts 
to combat multiple common instigators of atherogenesis. 
 
Experimental Procedures 
 
Reagents 
Polyclonal antibodies to p-ERK1/2 (Thr202/Tyr204; cat. No. 9101), p-Akt (Ser473; cat. 
No. 9271 and Thr308; cat. No. 2965), Myc, and MALT1 (cat. No. 2494) were from Cell 
Signaling Technology (Danvers, MA). Polyclonal antibodies to Bcl10 (sc-5611) and p65 
(sc-372-G) were from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal 
antibodies to PDK1 (sc-17765), HDAC1 (sc-81598), and GAPDH (sc-32233) were from 
39 
 
Santa Cruz, Biotechnology. Monoclonal antibody to p-IκBα (Ser32/34; cat. No. 9246) was 
from Cell Signaling Technology. Antibodies to tubulin (cat. No. T5168) and Flag (cat. No. 
F3165) were from Sigma (St. Louis, MO). Taqman  gene expression primers for 
quantitative RT-PCR were obtained from Applied Biosystems (Foster City, CA). Gene 
expression assay IDs for mouse GAPDH, VCAM-1, ICAM-1, and CARMA3 were 
Mm99999915, Mm00449197, Mm00516023, and Mm00459941, respectively. Thrombin 
(cat No. T4393), TRAP-6 (cat. No. T1573), and TNFα (cat. No. T6674) were purchased 
from Sigma. EGF (cat. No. E-3476) and insulin (cat. No. 12585-014) were from 
Invitrogen (Carlsbad, CA). IL-1β was from R&D Systems (Minneapolis, MN). The 
inhibitors AG1478 (cat. No. 658552), LY294002 (cat. No. 440204) and wortmannin (cat. 
No. 681676) were from EMD Chemicals (Gibbstown, NJ). Gene-specific siRNA oligos 
were obtained from Dharmacon (Lafayette, CO), utilizing the ON-TARGETplus 
smartpool format. In the case of CARMA3, a second siRNA pool was utilized, obtained 
from Qiagen (Germantown, MD). 
 
Plasmids 
The NF-κB-responsive luciferase reporter plasmid (pNF-κB-luciferase) was 
purchased from Stratagene (La Jolla, CA). Control renilla plasmid (phRL-TK) was from 
Promega (Madison, WI). The PDK1-myc and kinase-dead (KD) PDK1-myc plasmids 
were gifts from C. Sutherland and D. Alessi (University of Dundee). All other expression 
plasmids encoding tagged versions of Bcl10, CARMA3, or CARMA1 have been 
described previously (40,41). 
 
Quantitative RT-PCR 
Total RNA was prepared from cells using either the RNeasy Mini Kit (Qiagen) or 
with Trizol (Invitrogen). Equivalent amounts of RNA (500-1000ng) were used for cDNA 
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synthesis with the Superscript First-Strand Synthesis System (Invitrogen) using random 
primers. Quantitative PCR was performed using TaqMan  gene expression primers 
(Applied Biosystems) listed above, on an Applied Biosystems 7500 apparatus. Cycle 
thresholds (Ct) were determined and normalized with those for reactions performed with 
GAPDH-specific primers. Relative expression levels were determined using the 2-ΔΔCt 
method as described previously (42). 
 
Cell culture 
 SVEC4-10 mouse endothelial cells were obtained from ATCC and cultured in DMEM 
with 10% FBS. The generation of SVEC4-10 cells stably expressing an NF-κB-
responsive luciferase reporter plasmid has been described previously (43). Briefly, the 
reporter plasmid (pNF-κB-luciferase; Stratagene) was transfected along with a pSV2neo 
helper plasmid from Clontech (Palo Alto, CA). Cells were then cultured in the presence 
of G418 at a concentration of 500µg/ml. Approximately 3 weeks after transfection, G418-
resistant clones were isolated and analyzed for luciferase activity to obtain an optimally 
responsive line. The resulting line was then maintained in medium containing 300µg/ml 
G418. 
Primary endothelial cells were isolated from adult male Sprague-Dawley rat aorta 
using a method of sequential collagenase digestion (44). Briefly, rats were anesthetized 
and aortas were exposed through a midline incision. Aortas were then briefly perfused in 
vivo with PBS before being excised, cleaned of adventitia, and transferred to 10cm 
plates. Following additional flushing, the lumen of each aorta was filled with a 
collagenase solution using a syringe (2mg/ml type II collagenase; Worthington). 
Digestion of the intimal layer was allowed to proceed for 15 minutes at 37oC, after which 
time digestion was halted by flushing aortas three times with DMEM containing 20% 
FBS. Released endothelial cells were collected by centrifugation at 170xg and washed 
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prior to plating in EGM-2 endothelial growth media (Cambrex). To evaluate for 
contamination of VSMCs in endothelial preps, cells were immunostained using antibody 
against a-smooth muscle actin (anti-SMA; Sigma). Preps of endothelial cells were only 
used if <5% of cells stained positively for SMA. Primary endothelial cells were used for 
no more than 5 passages. 
 
Western analysis 
After lysing cells with RIPA buffer containing protease and phosphatase inhibitors, 
immunoblotting was performed as described (28). When analyzing transient induction of 
phosphorylated proteins (p-IκBα, p-Akt, p-ERK), cells were starved overnight in serum-
free media and then treated for the indicated periods of time with either 0.1U/ml 
thrombin, 100µM TRAP-6, 0.4ng/ml IL-1β, 0.1µg/ml EGF, 50nM insulin, or 10ng/ml 
TNFα in serum-free DMEM before harvesting for western analysis.  
 
Immunoprecipitation 
HEK293T cells were transfected with expression plasmids encoding tagged 
versions of Bcl10, CARMA3, CARMA1, or PDK1. Cells were harvested 24 hours later 
and lysed in 0.2% Nonidet P-40 lysis buffer. Immunoprecipitations were carried out using 
monoclonal anti-Flag (Sigma) as described (45). The products were then resolved by 
SDS-PAGE and detected by western blotting with polyclonal anti-myc (Santa Cruz 
Biotechnology). Samples of total lysate, prior to immunoprecipitation, were analyzed in 
parallel. 
 
Nuclear fractionation 
 Cytoplasmic and nuclear extracts were prepared using the NE-PER Nuclear and 
Cytoplasmic Extraction Reagents according to the manufacturer’s recommendations 
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(Thermo Scientific, Rockford, IL). Purity of the nuclear extracts was confirmed by 
Western blot for HDAC1.  
 
Transfection and luciferase reporter assay 
For transient transfection experiments, cells were transfected pNF-κB-luciferase 
and the phRL-TK control renilla plasmid (Promega) using FuGene6 (Roche). 36 hours 
later, cells were treated for an additional 5 hours with or without medium containing 
either 5U/ml thrombin or 0.125ng/ml IL-1β. In some cases, cells were cotransfected with 
expression vectors encoding wild-type PDK1 or a dominant negative, kinase-dead 
version of PDK1 (PDK1 KD). Cells were harvested and luciferase activity in lysates was 
measured with a dual luciferase reporter assay system (Promega) and LMax II384 
luminometer (Molecular Devices), as described (28).  
 
RNA interference 
Individual proteins were targeted with the use of siRNA pools from Dharmacon and 
Qiagen. In brief, cells were transfected with gene-specific siRNA, or non-targeting 
siRNA, at a concentration of 10-25nM using Lipofectamine RNAiMAX reagent 
(Invitrogen), according to the manufacturer’s instructions. Cells were allowed to recover 
for 48-72 hours in order to achieve maximal knock-down. 
 
Monocyte/endothelial adhesion 
SVEC4-10 cells were transfected with control or Bcl10-specific siRNAs and allowed 
to grow to confluence. After an overnight serum starvation, cells were then treated with 
or without 4U/ml thrombin for 6 hours. WEHI-274.1 mouse monocytes (ATCC) were then 
added to the culture medium (6x105 cells/well for a 6-well plate). Monocytes were 
allowed to attach for 10 minutes, followed by vigorous washing, and the number of 
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monocytes remaining attached to the endothelial monolayer were counted using an 
inverted bright-field microscope. For each well, the total number of attached monocytes 
was tallied in seven, random 20x fields.  
 
Statistics 
Data are expressed as mean ± SEM. Differences between groups were compared 
for significance using paired or unpaired 2-tailed Student’s t tests, as appropriate, with 
the assistance of GraphPad InStat software. P values of less than 0.05 were considered 
statistically significant.  
 
Animal models 
Animal care was provided in accordance with the Laboratory Animal Welfare Act, 
and all experimental protocols were approved by the University of Michigan Medical 
School Committee on the Use and Care of Animals (UCUCA). All mice were housed in a 
standard temperature controlled facility with a 12-hour light/dark cycle, and were 
provided with a standard chow diet and water ad libitum. Bcl10 deficient mice (Bcl10-/-) 
were generated as described and backcrossed onto the C57BL/6J background for more 
than 10 generations (46). ApoE deficient mice (ApoE-/-) were purchased from The 
Jackson Laboratory and have also been bred onto the C57BL/6J background. To 
generate double-knockout mice, the two strains were cross-bred using a standard 
approach. 
 
Atherosclerosis studies 
Male ApoE-/- and ApoE-/-Bcl10-/- mice between the ages of 48 and 103 days of age 
were implanted subcutaneously with osmotic minipumps (Alzet model 2004) designed to 
deliver Ang II at a continuous rate of 500ng/kg/min. After 28 days, mice were sacrificed 
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and aortic trees were dissected, opened longitudinally, stained with Oil-Red-O, and 
pinned on black wax, as previously described (47). For each aorta, the percent of total 
surface area (ascending, arch, and descending to point of the femoral artery bifurcation) 
involved by fatty streaks or frank atherosclerosis was quantified using Image-Pro Plus 
software (Media Cybernetics, Bethesda, MD) after obtaining images with a Spot Insight 
color camera system (Diagnostic Instruments). Positive Oil-Red-O staining was used as 
a guide in the analysis, but care was taken to use standard procedures, as outlined by 
Daugherty et al (48), for identification of all lesions regardless of whether or not they 
reacted with the stain. Specifically, lesions seen under the dissecting scope as areas of 
thickening, often due to smooth muscle proliferation or accumulation of non-neutral 
lipids, were included in the calculation of lesional area. 
 
Results 
 
Thrombin activates the canonical NF-κB pathway in mouse endothelial cells 
through PAR-1 
  The immortalized mouse endothelial cell line, SVEC4-10, has proven to be a valuable 
model system for evaluating pro-inflammatory responses in the vasculature (49). 
However, little is known about the sensitivity of these cells to thrombin. Here, we found 
that thrombin causes rapid activation of the canonical NF-κB pathway in SVEC4-10 
cells, as evidenced by the appearance of Ser32/36 phosphorylated IκBα (p-IκBα) in cell 
extracts within 10 minutes of treatment (Figure 2-1A). Other thrombin-responsive 
signaling pathways are also activated, including that for ERK (Figure 2-1A). 
 Of the various PAR family members, PAR-1 is the predominant member acting as a 
thrombin receptor in endothelial cells (6). To confirm that PAR-1 is functional in SVEC4-
10 cells, we performed a similar time course with a PAR-1 specific peptide agonist 
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(TRAP-6; SFLLRN). Results showed that TRAP-6 precisely mimics thrombin in its ability 
to induce the NF-κB and ERK pathways in SVEC4-10 cells, suggesting that PAR-1 likely 
mediates the thrombin response in these cells (Figure 2-1B). 
Most of the signaling cascades activated by PAR-1 are mediated through direct 
receptor-dependent stimulation of G-proteins and their downstream signaling factors. 
However, PAR-1 is also known to transactivate the EGF receptor (EGFR), thereby 
stimulating additional signaling cascades (5,50). To test whether the NF-κB activation 
observed following thrombin treatment might be secondary to EGFR transactivation, we 
co-treated cells with AG1478, an EGFR tyrosine kinase antagonist. While AG1478 
completely blocked ERK activation by thrombin, suggesting that stimulation of the ERK 
pathway in SVEC4-10 cells does indeed occur through EGFR transactivation, there was 
no effect on generation of p-IκBα (Figure 2-1C). Taken together, the results shown in 
Figure 2-1 indicate that SVEC4-10 endothelial cells display a robust canonical NF-κB 
response to thrombin, an effect that is likely mediated through direct downstream 
signaling from PAR-1. 
 
The CBM-complex mediates thrombin-dependent NF-κB activation 
We next employed an RNA interference approach to determine whether thrombin-
mediated induction of p-IκBα occurs through the CBM complex. Due to the lack of a 
sensitive and specific antibody for CARMA3, we used quantitative RT-PCR to 
demonstrate that siRNA targeting CARMA3 reduces mRNA levels for the protein by 
approximately 70% (the upper right panel in Figure 2-2A). Concomitant with this 
reduction in CARMA3, we observed a complete blockade in the ability of thrombin to 
induce p-IκBα (the upper left panel in Figure 2-2A). Conversely, the ability of TNFα to 
stimulate p-IκBα production remained intact, indicating specificity for the role of CARMA3 
in the thrombin response. Further, the reduction in CARMA3 levels did not impair other 
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signaling responses induced by thrombin, such as that for ERK activation, again 
indicating specificity for the role of CARMA3 in a select pathway (the upper left panel in 
Figure 2-2A).  
As a further confirmation of the essential role for CARMA3 in the thrombin-mediated 
induction of p-IκBα, we utilized an entirely different siRNA pool, prepared by a different 
manufacturer (Qiagen vs Dharmacon). This siRNA was nearly identical in its ability to 
reduce CARMA3 mRNA levels (the lower right panel in Figure 2-2A), and was also 
completely effective in blocking the thrombin induction of p-IκBα (the lower left panel in 
Figure 2-2A). Again, the siRNA had no impact on p-IκBα generation in response to an 
unrelated stimulus (IL-1β), and had no effect on thrombin-mediated ERK activation. 
We next tested the role of the other components of the CBM complex, and 
observed similar results. Knockdown of either Bcl10 or MALT1 completely blocked 
thrombin induction of p-IκBα, while not affecting the IL-1β response nor the ability of 
thrombin to activate ERK (Figure 2-2, B and C). In both cases, western analysis showed 
near complete reduction in the levels of the Bcl10 and MALT1 proteins, respectively, 
following siRNA transfection. Similarly, human endothelial cells, Ea.Hy926, were 
transfected with an siRNA pool targeting Bcl10, resulting in near complete reduction of 
Bcl10 protein levels. As with Bcl10 knock-down in mouse endothelial cells, SVEC4-10, 
the reduction in Bcl10 levels completely blocked thrombin-dependent p-IκBα generation 
(Figure 2-2D). 
 
PDK1 is not needed to bridge PAR-1 to the CBM complex 
Others have demonstrated a critical role for PI3K in mediating thrombin-induction of 
NF-κB responsive genes (2,22-24). Since PI3K activation causes rapid production of 
plasma membrane-associated phosphatidylinositol 3,4,5-tris-phosphate (PIP3), and 
subsequent recruitment of PDK1 through a PIP3-Pleckstrin Homology (PH) domain 
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interaction (51), we considered the possibility that the thrombin receptor, PAR-1, might 
communicate with the CBM complex through PDK1. As such, this would be analogous to 
the mechanism by which a CARMA1-containing CBM complex is recruited and activated 
in T lymphocytes, following ligand-activation of the antigen receptor complex, CD3/CD28 
(52-54). In the case of T-lymphocytes, PDK1 serves as a scaffold by directly binding 
both CARMA1 and PKC. This allows PKC to phosphorylate CARMA1, resulting in 
exposure of the CARMA1 caspase recruitment domain (CARD) which subsequently 
binds Bcl10/MALT1. Thus, PDK1 is thought to function as a central “nidus” for assembly 
of the activated CBM complex in the vicinity of the antigen receptor. 
To begin exploring the possible involvement of PDK1 in thrombin-dependent 
recruitment of the CARMA3-containing CBM complex, we used an immunoprecipitation 
approach to test whether CARMA3, like the lymphocyte-specific CARMA1, interacts with 
PDK1. Results showed that myc-tagged PDK1 co-immunoprecipitates with flag-tagged 
CARMA3, suggesting an interaction can occur between the two proteins (Figure 2-3A). 
Importantly, when we compared the ability of CARMA3 and CARMA1 to bind to PDK1, 
we found that the two CARMA proteins are reasonably similar in their apparent affinity 
for PDK1 (Figure 2-3B). 
Since recruitment of PDK1 to the membrane is dependent on PI3K activation and 
generation of PIP3, we asked whether chemical inhibition of PI3K would be sufficient to 
block thrombin-induced generation of p-IκBα, thereby suggesting impaired assembly of 
the CBM complex. Surprisingly, the well-known PI3K inhibitor, LY294002, had only a 
minimal effect on thrombin-induced p-IκBα generation in SVEC4-10 cells (Figure 2-4A). 
In contrast, LY294002 was completely effective at blocking thrombin- or insulin-induced 
phosphorylation of Akt, a known downstream substrate for the PI3K pathway, thereby 
demonstrating that the inhibitor was fully effective in eliminating PI3K activity in this 
context (Figure 2-4A). Similar results were seen with wortmannin, an inhibitor that blocks 
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PI3K activity through a mechanism different from that used by LY294002 (Figure 2-5). 
We also found that LY294002 had a minimal effect on the ability of thrombin to induce 
nuclear translocation of the p65 subunit of NF-κB, an event that occurs as a 
consequence of IκBα phosphorylation and degradation (Figure 2-4B). Thus, two 
independent measures of thrombin-induced canonical NF-κB activation are largely 
unaffected by PI3K inhibition. These results sharply contrast with what has been shown 
in T-cells stimulated with anti-CD3/CD28; in this case, both LY294002 and wortmannin 
completely block antigen receptor-dependent signaling to IκBα (53).  
As a more direct assessment of the functional role of PDK1 in the thrombin 
response, we then tested the effect of siRNA-mediated PDK1 knockdown in SVEC4-10 
cells. Results showed that although PDK1 levels were almost completely ablated by the 
siRNA, the thrombin response, as measured by p-IκBα generation, remained intact or 
was even slightly enhanced (Figure 2-4C). Similarly, PDK1 knockdown had no effect on 
thrombin-induced p65 nuclear translocation, while in contrast, Bcl10 knockdown 
completely prevented the accumulation of p65 in the nucleus (Figure 2-4D). Finally, 
when transiently expressed in SVEC4-10 cells, a kinase-dead, dominant negative 
mutant of PDK1 had no effect on thrombin-induced NF-κB activation, further supporting 
the notion that PDK1 has no significant role in mediating early steps in activation of the 
IKK complex or in the subsequent process of p65 nuclear translocation (Figure 2-4E). 
These results again contrast with what has been shown for antigen receptor-dependent 
canonical NF-κB signaling in T-cells, which is entirely dependent upon the presence and 
activity of PDK1 (52,53).  
Recently, Sun and Lin demonstrated that β-arrestin 2 can physically link the LPA 
receptor with CARMA3 (55). Thus, in the context of GPCR signaling, β-arrestin 2 could 
represent an alternative to PDK1, with regard to assembly of the CARMA3-containing 
CBM complex. As a result, we measured thrombin-dependent p-IκBα generation in 
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MEFs obtained from wild-type mice as compared to MEFs obtained from β-arrestin 2 
knockout mice. While the wild-type MEFs responded with a similar time course and 
magnitude of p-IκBα induction as was seen with SVEC4-10 cells, the β-arrestin 2 
knockout MEFs were completely unresponsive to thrombin (Figure 2-4F). In contrast, 
both MEF lines showed similar responsiveness to TNFα, indicating that β-arrestin 2 
deficiency was not impacting the NF-κB pathway in a global manner. 
In conclusion, despite the ability of PDK1 to physically interact with CARMA3 in co-
immunoprecipitation experiments, our data suggest that PAR-1 does not require PDK1 
for communication with the IKK complex. Instead, we find that PAR-1 depends upon β-
arrestin 2 for NF-κB activation. Thus, PAR-1, and perhaps several other GPCRs, may 
utilize a mechanism that is quite distinct from that utilized by antigen receptors for 
assembly of the CBM complex. 
 
The CBM complex is critical for thrombin induction of NF-κB-responsive gene 
transcription in endothelial cells 
Having definitively shown a requirement for all components of the CBM complex in 
mediating an early step in the process of thrombin-induced canonical NF-κB activation, 
namely IκBα phosphorylation, we next turned to an analysis of the role of the complex in 
mediating thrombin-dependent regulation of gene transcription. To this end, we 
evaluated SVEC4-10 cells with stable integration of an NF-κB-luciferase reporter and 
found that siRNA-mediated knockdown of Bcl10 resulted in profound impairment of 
thrombin-dependent luciferase expression (Figure 2-6). Induction of luciferase in 
response to IL-1β, however, was unaffected. 
We then asked whether disrupting the CBM complex would affect the ability of 
thrombin to enhance transcription of endogenous genes, using the ICAM-1 and VCAM-1 
genes as markers since they are known to be strongly induced by NF-κB (2). Preliminary 
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studies showed that, as in other endothelial cell systems, thrombin induced these genes 
in a time-dependent fashion in SVEC4-10 cells, with mRNA levels increasing within 2 
hours following thrombin treatment, and peak protein levels following shortly thereafter 
(not shown). We then used siRNA to block Bcl10 expression and found that this 
dramatically impaired the ability of thrombin to induce expression of both ICAM-1 and 
VCAM-1, as assessed by quantitative RT-PCR (Figure 2-7, A and B). Since induction of 
VCAM-1 is particularly relevant to atherogenesis, as a mechanism for promoting 
macrophage recruitment to the vessel wall, we also analyzed the impact of Bcl10 
knockdown on VCAM-1 protein levels. Both thrombin and IL-1β caused a robust 
induction of VCAM-1 protein in SVEC4-10 cells within 4-6 hours, but under conditions of 
Bcl10 knockdown, thrombin induction of VCAM-1 was almost completely blocked while 
the induction by IL-1β remained unaffected (Figure 2-7C). Taken together, these data 
demonstrate that the CBM complex is not only critical for proximal steps in canonical NF-
κB activation, but also for downstream regulation of NF-κB target genes. 
 
The CBM complex controls thrombin-dependent monocyte/endothelial adhesion 
Recruitment of monocytes to the vessel wall is initiated largely through the 
interaction of VCAM-1, on the surface of endothelial cells, with VLA-4, an α4β1 integrin 
expressed on circulating monocytes (56). This interaction causes either rolling of 
monocytes on the endothelial surface, or firm attachment when VLA-4 is in an activated 
conformation (57). Since we demonstrated that the CBM complex mediates thrombin-
dependent NF-κB activation and VCAM-1 expression in endothelial cells, we utilized an 
in vitro adhesion assay to determine whether disruption of the endothelial CBM complex 
would interfere with thrombin-induced monocyte/endothelial attachment. To this end, we 
grew SVEC4-10 endothelial cells to confluency, treated with thrombin for 6 hours, and 
then quantified the attachment of WEHI-274.1 mouse monocytes to the monolayer. 
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Endothelial cells transfected with control siRNA showed a nearly 4-fold increase in 
monocyte attachment following thrombin treatment, while those transfected with Bcl10-
specific siRNA showed only a 1.5-fold increase (Figure 2-8, A and B). These findings 
illustrate, for the first time, an essential role for the CBM complex in mediating a critical 
biologic response to thrombin, one with important implications for endothelial 
pathophysiology.  
 
Bcl10 deficiency protects ApoE-/- mice from GPCR-dependent atherogenesis 
We next sought to investigate the role of the CBM complex in mediating in vivo 
pathophysiologic consequences of GPCR-dependent pro-inflammatory signaling in the 
vasculature. However, systemic administration of thrombin in the in vivo setting has 
proven problematic, due to the potent pro-coagulant effect of thrombin. Previously, we 
had shown that the receptor for Ang II (AGTR1), which is closely related to PAR-1, 
utilizes the CBM complex to activate NF-κB in hepatocytes (58). Since Ang II also has a 
prominent role as a pro-inflammatory factor in vascular biology, promoting endothelial 
dysfunction in a manner similar to thrombin, we first asked whether Ang II might also 
stimulate the CBM complex in endothelial cells, and thus represent an alternative to 
thrombin for in vivo testing. To this end, we prepared cultures of primary endothelial cells 
from fresh rat aorta. We confirmed the role of the CBM complex in primary endothelial 
cells by showing that siRNA-mediated Bcl10 knockdown was effective at specifically 
blocking Ang II-dependent IκBα phosphorylation (Figure 2-9A). Thus, similar to what we 
had observed in hepatocytes, the CBM complex appears to mediate Ang II-dependent 
canonical NF-κB signaling in vascular cells.  
We then evaluated the effect of Bcl0 deficiency on Ang II-induced atherogenesis in 
ApoE-/- mice. These mice suffer from premature atherosclerosis due to hyperlipidemia. 
However, chronic infusion of Ang II, which mimics the relatively common clinical problem 
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of renin-angiotensin system (RAS) dysfunction, substantially accelerates the process 
(48). We crossed ApoE-/- mice with Bcl10-/- mice, and then compared the degree of 
atherosclerosis in ApoE-/- versus ApoE-/-Bcl10-/- mice infused for 4 weeks with Ang II. We 
observed a dramatic decrease in the extent of atherosclerosis in ApoE-/-Bcl10-/- mice as 
compared to ApoE-/- mice (Figure 2-9B, C). Thus we show that CBM complex is a 
mediator of GPCR-dependent atherogenesis in vivo.  
 
Discussion 
Thrombin is now well-recognized for exerting pro-inflammatory effects on the 
vasculature, particularly through its actions on endothelial cells. While many of these 
effects are mediated by activation of the NF-κB transcription factor, and downstream 
induction of NF-κB -responsive genes, the mechanisms linking thrombin receptors to the 
canonical NF-κB machinery are incompletely understood. In this study, we show that a 
signaling complex composed of the CARMA3, Bcl10, and MALT1 proteins (CBM 
complex) serves as a molecular bridge to link activated thrombin receptors to the IκBα 
kinase. Further, we demonstrate that the CBM complex is essential for thrombin to 
activate transcription of key genes that underlie the pathogenesis of atherosclerosis, 
particularly those that mediate recruitment of inflammatory cells to the vessel wall. 
To date, a select group of GPCRs have now been shown to utilize the CBM 
complex for activation of the canonical NF-κB pathway. In addition to the thrombin 
receptor (PAR-1), these include the receptors for angiotensin II (Ang II), 
lysophosphatidic acid (LPA), endothelin-1, platelet activating factor (PAF), IL-8 (CXCL8), 
and SDF-1(CXCL12) (25-33). PAR-1 is unique among these in that it is not activated by 
a circulating ligand. Rather, PAR-1 utilizes a tethered ligand that is present within the 
extracellular domain of the receptor itself, but is masked by an amino-terminal sequence 
that can be removed via proteolytic cleavage by thrombin (1). Once the amino-terminal 
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sequence is removed, the tethered ligand is free to interact with the ligand-binding 
pocket of the receptor and activate downstream signaling. Many other differences exist 
between these receptors, including their preferences for coupling to specific G protein 
families including Gαi, Gαq, and Gα12/13 (59,60). 
Despite their differences, GPCRs in this group do share some common properties. 
In particular, all are capable of activating PKC isoforms through Gαq (59,60). We 
speculate that the PKC isoforms activated by these receptors phosphorylate CARMA3, 
thereby exposing the CARMA3 CARD and allowing for CARD-dependent recruitment of 
Bcl10 and MALT1. As such, this mechanism for assembly of the CBM complex would be 
analogous to that which occurs in B- and T-lymphocytes, following stimulation of antigen 
receptor (34-37).  
Clearly, however, many GPCRs are capable of activating PKC, but not all of these 
GPCRs are effective at stimulating NF-κB and perhaps even fewer will be found to utilize 
the CBM complex. What are the distinguishing features that identify the group of GPCRs 
that effectively communicate with the CBM complex? The answer to this question is 
completely unknown, but may lie in discovering additional signaling intermediates, 
besides PKC, that bridge selected GPCRs with the CBM complex. To gain further 
insight, we looked for clues by studying the well-characterized activation of the 
analogous CARMA1-containing CBM complex in lymphocytes. In T-cells, strong 
evidence implicates PDK1 as a scaffolding protein that brings together activated PKC 
and CARMA1 following CD3/CD28 stimulation (52-54). In this case, stimulation of CD3 
activates PKCθ, while stimulation of the CD28 co-receptor activates PI3K and induces 
PDK1 membrane recruitment (Figure 2-10). PDK1 then binds to both PKC and 
CARMA1, facilitating the ability of PKC to recognize CARMA1 as a substrate and induce 
its phosphorylation.  
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Importantly, PAR-1 is known to activate PI3K in addition to PKC (1). Thus, we 
wondered if this single receptor might be capable of activating two separate signal 
transduction pathways that converge on CARMA3, a feat that in the lymphocyte requires 
stimulation of two distinct receptors, CD3 and CD28 (Figure 2-10). We therefore tested 
whether PI3K and PDK1 might be similarly important for the ability of PAR-1 to 
communicate with the CARMA3-containing CBM complex. As such, this could represent 
an additional level of control and potentially provide insight into the mechanisms 
governing the use of the CBM complex by only selected GPCRs. 
However, despite evidence suggesting that a physical interaction can occur 
between PDK1 and CARMA3, we found that PDK1 knockdown by RNA interference had 
absolutely no impact on the thrombin-dependent NF-κB response, nor did expression of 
a PDK1 dominant negative mutant. PI3K inhibitors were also largely ineffective at 
blocking thrombin-induced p-IκBα generation and p65 nuclear translocation. These 
results suggest that a significant difference exists between the mechanism utilized by 
PAR-1 for communication with the CARMA3-containing CBM complex and that utilized 
by CD3/CD28 for communication with the CARMA1-containing CBM complex. 
It is intriguing to speculate that the difference may extend to multiple GPCRs, 
besides PAR-1. In fact, recent work by Sun and Lin provide an alternative explanation as 
to how GPCRs may communicate with the CBM complex (55). These researchers 
demonstrated that MEFs from β-arrestin 2 knock-out mice were unable to respond to 
LPA with phosphorylation of IκBα. In addition, β-arrestin 2 was found to not only bind 
CARMA3, but to also mediate an indirect physical interaction between the LPA receptor 
and CARMA3. Thus, β-arrestin 2 is an essential mediator of LPA-induced NF-κB 
activation. We similarly found that thrombin induction of p-IκBα is completely impaired in 
β-arrestin 2 knockout MEFs, while wild-type MEFs maintain a robust response. The 
arrestins are a small family of proteins known for their complex roles in GPCR signaling, 
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and while some family members function only in the retina, two others, β-arrestin 1 and 
2, are expressed ubiquitously and impact GPCR-dependent signaling more broadly 
(61,62). In some cases, the arrestins work to terminate GPCR signaling activity, but in 
other cases they function as critical positive mediators of signaling. Due to this complex, 
nuanced role in regulating GPCR activity, one might imagine that specific arrestins could 
dictate which GPCRs communicate with the CBM complex, possibly in a cell-type 
specific manner. Based on our work and that of Sun and Lin, we suggest that in certain 
non-hematopoietic cells, such as endothelial cells, β-arrestin 2 replaces PDK1 as a 
scaffold for assembly of CARMA3-containing CBM complexes, in response to ligation of 
specific GPCRs that include PAR-1 and the LPA receptor (Figure 2-10). 
It is important to place our current work into the context of what is already known 
regarding thrombin induction of both ICAM-1 and VCAM-1. As noted earlier, NF-κB 
activation is a cornerstone in the regulation of these two genes, but other signal 
transduction events are also required to achieve optimal induction, some of which are 
specific to one gene or the other. Most relevant to our work is the fact that thrombin-
induced PI3K activation is clearly crucial for the ultimate induction of both genes (2,22-
24), even though our studies indicate that PI3K activity is not particularly important for 
the proximal steps in the canonical NF-κB activation pathway, at least not for those 
leading to phosphorylation of IκBα and p65 nuclear translocation.  
It is therefore likely that the crucial role of PI3K lies in its stimulation of parallel 
pathways regulating ICAM-1 and VCAM-1 transcription. For example, it is clear that 
VCAM-1 induction depends not only on NF-κB activation, but also on simultaneous 
activation of the GATA-2 transcription factor, which is PI3K dependent (Figure 2-10) 
(2,24,63). Others have shown that Akt activation, following thrombin-induced PI3K 
stimulation, is important for induction of ICAM-1 gene expression (23). However, it 
remains uncertain as to precisely how Akt contributes. While evidence exists that Akt 
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can directly phosphorylate components of the IκB kinase complex, contributing to its 
activation, this action of Akt appears to mostly impact IKKα and the non-canonical NF-κB 
pathway (64-67). Thus, in the setting of thrombin stimulation, Akt-responsive IKKα 
activation may not be sufficient for robust stimulation of the canonical pathway, leading 
to IκBα phosphorylation, without the contributions of the CBM complex. Another 
explanation for the role of Akt stems from the observation that Akt can phosphorylate the 
p65 subunit of NF-κB, an event that increases its transcriptional capacity (Figure 2-10) 
(68-70). Finally, PI3K activation can lead to stimulation of NADPH oxidase and 
generation of reactive oxygen species (ROS) (71). Since NF-κB is a redox-sensitive 
transcription factor (72), this is yet another mechanism whereby PI3K may play a critical 
role in the downstream regulation of NF-κB-responsive gene transcription, without 
playing a dramatic role in CBM complex-dependent IκBα phosphorylation and p65 
nuclear translocation.  
In summary, we show here that the CBM complex plays a critical role in mediating 
an important pathophysiologic response to thrombin, namely the induction of adhesion 
molecules on the surface of endothelial cells exposed to thrombin. This is an important 
event in a variety of conditions since adhesion molecules mediate the recruitment of 
inflammatory cells to sites of injury. The decreased rate of atherosclerosis observed in 
Bcl10-deficient mice and the reduced monocyte/endothelial cell adhesion we observed 
with Bcl10 knockdown suggest that the CBM complex may be required for both thrombin 
and Ang II to effectively promote monocyte/macrophage recruitment for atherosclerotic 
plaque formation. In the case of atherogenesis, injury may be initiated by the chronic 
deposition of cholesterol in the vessel wall, with subsequent plaque rupture and 
thrombus formation. Thrombin generated locally in response to this injury stimulates 
recruitment of a variety of leukocytes through induction of ICAM-1 and VCAM-1, which 
may further exacerbate the problem. However, similar cycles of injury and thrombosis 
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may occur at sites of trauma and/or infection, where thrombin induction of adhesion 
molecules is beneficial and necessary for the wound-healing response. While further 
work will be required to understand how PAR-1 communicates with the CBM complex, 
there now exists potential for targeting the complex in treatment of vascular conditions, 
such as atherosclerosis, where thrombin-induced NF-κB activation plays a pathologic 
role. This goal is potentially within grasp since an inhibitor of the MALT1 protease, the 
enzymatically active component of the complex, has now been described (73). Thus, the 
CBM complex is “drugable”, and therefore represents an attractive target for 
pharmaceutical development.  
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Figure 2-1. Canonical NF-κB activation through PAR-1 in SVEC4-10 endothelial 
cells. A, SVEC4-10 cells were treated with thrombin for varying periods of time before 
harvesting and analyzing by western blot. Within 10 minutes, thrombin induces the 
phosphorylation of IκBα, a marker of canonical NF-κB signaling. ERK activation, as 
evidenced by the appearance of p-ERK, occurs within 5 minutes. B, SVEC4-10 cells 
were similarly treated with a peptide that specifically activates PAR-1 (TRAP-6; 
SFLLRN). The time course for phosphorylation of IκBα and ERK was identical to that 
observed with thrombin stimulation. C, SVEC4-10 cells were treated with the indicated 
agonists (thrombin, EGF, or IL-1β) in the presence or absence of 50nM AG1478, an 
inhibitor of the EGFR tryrosine kinase. AG1478 was effective at completely eliminating 
both basal and induced levels of p-ERK, indicating that the EGFR is primarily 
responsible for ERK activation in these cells and that the inhibitor was fully active. In 
contrast, generation of p-IκBα by thrombin was unaffected, suggesting that thrombin-
dependent stimulation of the canonical NF-κB pathway is a direct effect of PAR-1, and 
not mediated through cross-activation of EGFR. 
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Figure 2-2. The CBM complex mediates thrombin-dependent NF-κB activation in 
endothelial cells. A, SVEC4-10 cells were transfected with independent siRNA pools 
targeting CARMA3, designed by Dharmacon (upper panel) or Qiagen (lower panel), at a 
concentration of 20 and 10nM, respectively. 48 hours following transfection, cells were 
treated with thrombin for the indicated periods of time, or for 5 minutes with TNFα or IL-
1β. Cells were harvested and analyzed by western blotting with the indicated antibodies. 
CARMA3 knockdown completely abrogated p-IκBα generation following thrombin 
treatment, but had no effect on the response to either TNFα or IL-1β. In addition, the 
impact of CARMA3 on thrombin signaling was specific to the canonical NF-κB pathway, 
since CARMA3 knockdown had no effect on the ability of thrombin to induce p-ERK. 
CARMA3 mRNA knockdown was assessed by quantitative RT-PCR, shown at right; (*) 
p<0.05. B, SVEC4-10 cells were similarly transfected with an siRNA pool targeting Bcl10 
(10nM), resulting in near complete reduction of Bcl10 protein levels as determined by 
western blotting. As with CARMA3 knock-down, the reduction in Bcl10 levels completely 
blocked thrombin-dependent p-IκBα generation while not affecting the response to IL-1β, 
and while not impacting the ability of thrombin to induce p-ERK. C, SVEC4-10 cells were 
similarly transfected with an siRNA pool targeting MALT1 (10nM), resulting in complete 
reduction of MALT1 levels as determined by western blotting. As seen in A and B, 
thrombin-dependent p-IκBα generation was specifically blocked under these conditions. 
D, Ea.Hy926 (human endothelial cells) were similarly transfected with an siRNA pool 
targeting Bcl10 (10nM) for 72 hours, resulting in near complete reduction of Bcl10 
protein levels as determined by western blotting. As with Bcl10 knock-down in SVEC4-
10, the reduction in Bcl10 levels completely blocked thrombin-dependent p-IκBα 
generation. 
D 
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Figure 2-3. Like CARMA1, CARMA3 is capable of interacting with PDK1. A, Flag-
tagged CARMA3 was expressed in 293T cells along with potential myc-tagged binding 
partners, as indicated. Cells were harvested and subjected to immunoprecipitation with 
anti-flag. The presence of co-immunoprecipitated proteins was analyzed by western 
blotting (top panel). A small fraction of the total PDK1 effectively co-immunoprecipitated 
along with CARMA3. In control samples, wild-type Bcl10 was seen to                            
co-immunoprecipitate efficiently, producing a ladder of bands that represent 
phosphorylated forms of the protein, while as expected, a Bcl10 mutant (L41Q) that has 
a disrupted CARD interaction domain did not co-immunoprecipitate. B, The relative 
efficiency of PDK1 co-immunoprecipitation was analyzed for CARMA3, in comparison to 
CARMA1. While the difference was not dramatic, CARMA3 appeared to be slightly less 
effective than CARMA1 at interacting. with PDK1. 
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Figure 2-4. PDK1 is dispensable for thrombin-dependent activation of canonical 
NF-κB. A, SVEC4-10 cells were pretreated for 1 hour with DMSO vehicle or with 50µM 
LY294002. Cells were then treated with thrombin for varying periods of time, or with 
insulin for 5 minutes. Cells were harvested and analyzed by western blotting with the 
indicated antibodies. The inhibitor had a minimal effect on thrombin induction of p-
IκBα, while completely blocking phosphorylation of Akt (p-Akt Ser473) in response to 
either thrombin or insulin. As expected, thrombin-induced ERK phosphorylation was 
not affected by LY294002, showing specificity for the effects of the inhibitor at the 
50µM dose. B, SVEC4-10 cells were similarly treated with DMSO or 50µM LY294002 
prior to thrombin stimulation for 20 minutes. Cells were then lysed and the nuclear 
fraction was isolated and analyzed for p65 nuclear translocation by western blotting 
(upper panel). As a loading control, nuclear fractions were also evaluated for the 
presence of the constitutive nuclear factor, HDAC1. Thrombin-dependent p65 nuclear 
translocation was largely unaffected by LY294002. As a control, TNFα treatment was 
also seen to induce nuclear accumulation of p65, an effect that was similarly unaltered 
by LY294002. In parallel wells, cells were treated with or without thrombin, TNFα, and 
LY294002, as indicated, prior to preparing whole cell lysates and blotting for p-Akt308 
(lower panel). As in panel A, this control demonstrates that the LY294002 compound 
was fully active at blocking PI3K activity within the context of the experiment. C, 
SVEC4-10 cells were transfected with an siRNA pool targeting PDK1 (25nM; Qiagen), 
resulting in complete knockdown of PDK1 levels by 48 hours. Cells were then treated 
with thrombin for the indicated periods of time, or with IL-1β for 5 minutes. PDK1 
knockdown had no detrimental effect on the ability of thrombin to stimulate p-IĸBα 
production. D, SVEC4-10 cells were transfected with siRNA pools, as indicated, and 
treated with thrombin for 20 minutes before harvesting. Nuclear fractions were isolated 
and probed for p65, while separate cytoplasmic fractions were probed to assess 
knockdown efficiency for either Bcl10 or PDK1. While Bcl10 knockdown completely 
abrogated thrombin-induced p65 nuclear translocation, PDK1 knockdown had no 
effect. E, SVEC4-10 cells were transfected with NF-κB-luciferase and control renilla 
reporter plasmids, in the presence or absence of co-transfected wild-type (WT) and 
kinase-dead, dominant negative (KD) PDK1 expression vectors as indicated. Cells 
were then treated for 5 hours with or without thrombin. Cells were harvested and the 
resulting NF-κB induction was measured by calculating the luciferase/renilla ratio. The 
kinase-dead, PDK1 dominant negative mutant was unable to block thrombin-induced 
NF-κB activation under these conditions. Results are expressed as fold NF-κB 
induction ± SEM, and are representative of three experiments. Expression of the PDK1 
proteins was evaluated by western blotting (insert), using the same extracts as used 
for the luciferase assay. F, Wild-type and β-arrestin 2 knockout MEFs were treated 
with thrombin for the indicated periods of time, or with TNFα for 5 minutes. Cells were 
harvested and analyzed for IκBα phosphorylation. Results demonstrated that wild-type 
MEFs respond to both thrombin and TNFα with p-IκBα generation, but β-arrestin 2 
knockout MEFs are completely unresponsive to thrombin, while maintaining their 
responsiveness to TNFα. 
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Figure 2-4. PDK1 is dispensable for thrombin-dependent activation of canonical 
NF-κB. 
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Figure 2-5. The PI3-kinase inhibitor, wortmannin, has little effect on the thrombin-
induced p-IκBα response. SVEC4-10 cells were pretreated for 1 hour with DMSO 
vehicle or with 100nM wortmannin. Cells were then treated with thrombin for varying 
periods of time, or with insulin for 5 minutes. Cells were harvested and analyzed by 
western blotting with the indicated antibodies. The inhibitor had only a modest effect on 
thrombin induction of p-IκBα, while completely blocking phosphorylation of Akt in 
response to either thrombin or insulin. As expected, thrombin induced ERK 
phosphorylation was not affected by wortmannin, showing specificity for the effects of 
the inhibitor at the 100nM dose. 
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Figure 2-6. Bcl10 knockdown blocks thrombin-responsive NF-κB reporter activity. 
SVEC4-10 cells stably expressing the NF-κB-luciferase reporter were transfected with 
either a control siRNA pool or with an siRNA pool targeting Bcl10, as described in Figure 
2-2. After 48 hours, cells were treated for an additional 5 hours with either thrombin or 
IL-1β. Cells were harvested and NF-κB induction was assessed by measuring luciferase 
levels, corrected for cell number. Lysates were also analyzed for Bcl10 knockdown by 
western blotting (insert). Results showed that Bcl10 knockdown dramatically reduced 
NF-κB activation by thrombin, but had no effect on the activation achieved with IL-1β. 
Results represent the average of 3 independent experiments, ± SEM; (*) p<0.05. 
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Figure 2-7. Bcl10 knockdown blocks thrombin-responsive induction of endothelial 
adhesion molecules. A and B, SVEC4-10 cells were transfected with control or Bcl10-
specific siRNA as in Figure 2-2. After 48 hours, cells were treated an additional 2 hours 
with thrombin or IL-1β. Cells were harvested and assayed for ICAM-1 (A) or VCAM-1 (B) 
mRNA expression by quantitative RT-PCR. Results are expressed as percent maximal 
induction and represent the mean ± SEM for 3 determinations; (*) p<0.05. C, Similar to 
parts A and B above, SVEC4-10 cells were transfected with control or Bcl10 siRNA and 
allowed to recover for 48 hours. Cells were then treated with thrombin or IL-1β for the 
indicated periods of time before harvesting and subjecting to western analysis. 
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Figure 2-8. Thrombin-induced monocyte/endothelial adhesion is dependent on an 
intact endothelial CBM complex. A and B, SVEC4-10 cells were transfected with 
control or Bcl10 siRNA as above, and were allowed to then grow to confluence, 
producing a monolayer. Cells were then treated with or without thrombin for 6 hours to 
induce adhesion molecule expression. WEHI-274.1 monocytes were then added to the 
culture medium and allowed to settle onto the endothelial monolayer. After 10 minutes, 
unattached monocytes were removed by washing, and monocyte-endothelial attachment 
was measured by counting adherent monocytes in seven 20x fields per condition. 
Representative bright-field micrographs of individual 20x fields are shown in (A). 
Quantification of the fold increase in monocyte adherence is shown in (B). Results 
represent the average of 9 independent determinations ± SEM; (**) p<0.01. 
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FIGURE 2-9. Bcl10 deficiency protects ApoE-/- mice from Ang II-dependent 
atherogenesis. A, Primary rat aortic endothelial cells were transiently transfected with 
Bcl10 siRNA as in previous panels, and Ang II/TNFα-dependent p-IκBα generation was 
assayed as above. B, Aortas from the ApoE-/- (n=22) and ApoE-/-Bcl10-/- (n=13) groups 
following 4 weeks of chronic Ang II infusion (500ng/kg/min) and Oil Red O staining. The 
most significantly affected aortic segments from both groups are shown. The aortic arch 
and major arterial branches extending from the arch for a representative mouse in each 
group are also shown. C, Quantification of atherosclerotic lesion area for all mice is 
shown, presented as the percentage of the surface area of the entire aorta (ascending, 
arch, and descending to point of the femoral artery bifurcation) stained positively with Oil 
Red O. The average percentage of area covered by lesion is indicated by an orange bar, 
and the S.E. is indicated by blue error bars. 
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Figure 2-10. Schematic comparing CBM-dependent signaling in endothelial cells 
and lymphocytes. A schematic diagram illustrating potential differences between the 
mechanisms for recruitment and activation of the CARMA3-containing complex in 
endothelial cells (left) and the CARMA1-containing complex in T cells (right). See text for 
further description. It should be noted that Narayan, P.  et al. 2006, found that while TCR 
could activate the Akt pathway, it did not  phosphorylate IKKβ. Instead, they infer a 
possible role for Akt kinase activity, modulating activation of CBM complex dependent 
NF-κB signaling via Akt binding to CARMA1 then phosphorylating Bcl10.This activity 
was not exclusively necessary for NF-κB signaling. For an excellent review of CARMA1 
in CBM complex signaling, please see Rawlings, D.J. and et al. 2006 (35). 
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Chapter III 
 
Protease-Activated Receptor 1 Activates Parallel Pathways Which Modulate the 
Receptor’s Impact on NF-κB Signaling 
 
Abstract 
Endothelial dysfunction is caused by chronic inflammation and enhanced NF-κB 
activity that alters the properties of the endothelium. This is recognized as the earliest 
stage of atherosclerosis. PAR-1 is a member of the G protein-coupled receptor 
superfamily that activates intracellular signaling pathways through heterotrimeric G 
protein-dependent and -independent mechanisms that affect gene expression, monocyte 
adhesion, endothelial permeability, and vascular tone. The canonical role of β-arrestins 
in GPCR biology is to desensitize activated receptors. This is done through receptor 
phosphorylation by G protein receptor kinases (GRKs), which recruit β-arrestins to the 
receptors. Recently, β-arrestins have also become recognized as scaffold proteins that 
enable the recruitment and activation of signaling pathways downstream of GPCRs, 
including the NF-κB pathway. After stimulation, β-arrestin 2 recruits CARMA3 to the LPA 
and thrombin receptors. By facilitating the formation of the CARMA3/Bcl10/MALT1 
(CBM) complex, it activates the NF-κB pathway. We demonstrate that multiple parallel 
pathways, in addition to the β-arrestin 2/CBM complex we previously reported, connect 
PAR-1 to the activation of the NF-κB pathway. These parallel pathways, RhoA/ROCK 
and PI3K/Akt, appear to originate from the recruitment of β-arrestin 1 to the receptor and 
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possibly contribute to the phosphorylation of the IKK complex. In the process of 
identifying the GRK involved in the β-arrestin recruitment, we identified a novel negative 
regulator of PAR-1-dependent NF-κB signaling, GRK2. GRK2 negatively regulates PAR-
1-dependent NF-κB activation through its ability to desensitize PAR-1 and/or its ability to 
block PI3K/Akt activity in the NF-κB pathway. All of these pathways represent multiple 
layers of PAR-1-dependent NF-κB activation that are needed to control a powerful 
pathway from causing endothelial dysfunction while allowing the plasticity to respond to 
various stimuli correctly. 
 
Introduction 
Endothelial dysfunction is considered the earliest condition leading to 
atherosclerosis and is broadly defined as the stimulation of the endothelium to the 
deleterious effect of the organism (1,2). This stimulation, often attributed to high levels of 
LDL, causes a chronic inflammation with enhanced NF-κB activity that significantly alters 
endothelial properties, leading to atherosclerosis (3,4). Both PAR-1 and thrombin are 
major participants in atherogenesis, affecting cell signaling, gene expression, endothelial 
permeability, and vascular tone (5,6). Thrombin, a protease, binds to the extracellular N-
terminus of the GPCR PAR-1. It then cleaves a specific sequence, exposing a cryptic 
self-ligand that binds to the receptor. This activates intracellular signaling pathways 
through heterotrimeric G protein activation that are then subsequently desensitized (7,8). 
Desensitization starts with the phosphorylation of intracellular domains of an activated 
GPCR by one or more members of the G protein receptor kinase (GRK) family, which 
recruit β-arrestins to the phosphorylated receptor (9). The canonical role of β-arrestins is 
to uncouple G proteins by inhibiting the GPCR from constitutively acting as a guanine 
nucleotide exchange factor (GEF) for heterotrimeric G proteins (10,11). More recently, a 
“non-canonical” role has been described wherein β-arrestin 1 and β-arrestin 2 act as 
75 
 
scaffold proteins that facilitate the recruitment and activation of a separate set of 
signaling pathway components downstream of activated GPCRs such as ERK, JNK and 
p38 MAPK (9,12).  
As described in chapter 2, β-arrestin 2 has been revealed to recruit CARMA3 to 
the stimulated LPA and thrombin receptors to induce the NF-κB pathway (13,14). When 
β-arrestin 1-/- MEFs and β-arrestin 2-/- MEFs are treated with LPA, only the loss of β-
arrestin 2, but not β-arrestin 1, inhibits NF-κB activation (14). CARMA3 functions as a 
scaffold protein that, through its CARD domain, binds to the CARD domain of Bcl10 (15). 
Bcl10 then acts as an adaptor between CARMA3 and the Ig-like domains of MALT1 
(16). MALT1 binds to TRAF6 which in turn causes the K63-linked polyubiquitination of 
the entire CBM complex (17,18). The IKK complex binds to ubiquitin chains of the CBM 
complex, allowing TRAF6 to induce K63-linked polyubiquitination of the IKK complex. 
The IKK complex is then phosphorylated by a signaling pathway parallel to the CBM 
complex, such as MEKK3 in the case of the LPA receptor. This completes the activation 
of the IKK complex, allowing it to phosphorylate IκBα, leading to proteasomal 
degradation of the latter and the release of the NF-κB transcription factors (19-21).  
Here we report that not only is PAR-1 recruitment of β-arrestin 2 necessary for 
NF-κB activation via the CBM complex, but β-arrestin 1 is equally necessary. β-arrestin 
1 appears to act as a signaling node, possibly activating the RhoA/ROCK and PI3K/Akt 
kinase pathways, which we show is necessary for PAR-1-dependent NF-κB activation. 
Finally, while investigating the role of G protein receptor kinases (GRKs) in recruiting the 
β-arrestins to PAR-1, we identify a new role of GRK2 as a negative regulator of NF-κB 
activation.  
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Experimental Procedures 
Reagents 
 A polyclonal antibody to p-ERK1/2 (Thr202/Tyr204; cat. No. 9101) was from Cell 
Signaling Technology (Danvers, MA). Polyclonal antibody to GRK2 (sc-562) was from 
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody GAPDH (sc-32233) 
was from Santa Cruz, Biotechnology. Monoclonal antibody to VCAM-1 was from R&D 
Systems. Monoclonal antibodies to p-IκBα (Ser32/34; cat. No. 9246) and p-Akt (Ser473; 
cat. No. 4060) were from Cell Signaling Technology. Antibody to tubulin (cat. No. T5168) 
was from Sigma (St. Louis, MO). Thrombin (cat No. T4393) and TNFα (cat. No. T6674) 
were purchased from Sigma. IL-1β was from R&D Systems (Minneapolis, MN). Y-27632 
(cat No. 10005583) was from Cayman Chemical (Ann Arbor, MI). Gene-specific siRNA 
oligos were obtained from Dharmacon (Lafayette, CO), utilizing the ON-TARGETplus 
smartpool format.  
 
Plasmids 
 The NF-κB-responsive luciferase reporter plasmid (pNF-κB-luciferase) was 
purchased from Stratagene (La Jolla, CA). Control renilla plasmid (phRL-TK) was from 
Promega (Madison, WI).  
 
Cell culture 
 SVEC4-10 mouse endothelial cells were obtained from ATCC and cultured in 
DMEM with 10% FBS. The generation of SVEC4-10 cells stably expressing an NF-κB-
responsive luciferase reporter plasmid has been described previously (22). Briefly, the 
reporter plasmid (pNF-κB-luciferase; Stratagene) was transfected along with a pSV2neo 
helper plasmid from Clontech (Palo Alto, CA). Cells were then cultured in the presence 
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of G418 at a concentration of 500µg/ml. Approximately 3 weeks after transfection, G418-
resistant clones were isolated and analyzed for luciferase activity to obtain an optimally 
responsive line. The resulting line was then maintained in media containing 300µg/ml 
G418. These SVEC4-10 reporter cells were a kind gift of Dr. Yoshiyuki Hattori. 
Characterization and culturing of β-arrestin 1-/- and β-arrestin 2-/- MEFs were described 
previously by Kohout et al. (23). These MEFs were a kind gift of Dr. Robert Lefkowitz. 
 
Western analysis 
 After lysing cells with RIPA buffer containing protease and phosphatase 
inhibitors, immunoblotting was performed as described (24). When analyzing transient 
induction of phosphorylated proteins (p-IkBα, p-Akt, p-ERK), cells were starved overnight 
in serum-free media and then treated for the indicated periods of time with either 0.2U/ml 
thrombin in SVEC4-10 and 1U/ml in MEFs, 0.4ng/ml IL-1β, or 10ng/ml TNFα in serum-
free DMEM before harvesting for western analysis. 
 
Transfection and luciferase reporter assay 
 For transient transfection experiments, cells were transfected with pcDNA3-
GRK2, pNF-κB-luciferase and the phRL-TK control renilla plasmid (Promega) using 
FuGene6 (Roche). 36 hours later, cells were treated for an additional 5 hours with or 
without media containing either 5U/ml thrombin or 0.125ng/ml IL-1β. Cells were 
harvested and luciferase activity in lysates was measured with a dual luciferase reporter 
assay system (Promega) and LMax II384 luminometer (Molecular Devices), as described 
(24).  
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RNA interference 
 Individual proteins were targeted with the use of siRNA pools from Dharmacon. 
In brief, cells were transfected with gene-specific siRNA, or non-targeting siRNA, at a 
concentration of 10nM using Lipofectamine RNAiMAX reagent (Invitrogen), according to 
the manufacturer’s instructions. Cells were allowed to recover for 48 hours in order to 
achieve maximal knock-down. 
 
Results 
 
Thrombin-dependent NF-κB signaling requires both β-arrestin 1 and β-arrestin 2  
 PAR-1 is a well-established activator of multiple cell signaling pathways that play 
key roles in endothelial biology. PAR-1-dependent NF-κB activity is reliant on several 
receptor-proximal proteins being activated: Gαq, Gβγ, PKC-δ and PI3K (25-28). 
Additionally, β-arrestin 1 and β-arrestin 2 function in the role of scaffold proteins for 
GPCR-dependent cell signaling. This scaffold function has been well described for 
GPCR-dependent ERK, Akt and JNK signaling (Table 3-1) (29). Using β-arrestin 2-/- 
MEFs, we recently reported that PAR-1-dependent NF-κB signaling was blocked and 
Sun et al. demonstrated that β-arrestin 2 binds to CARMA3 to act as a bridge to the 
active LPA receptor for NF-κB signaling (13,14).  
While β-arrestin 1 is not required for LPA receptor-dependent NF-κB signaling, β-
arrestin 1 is necessary for numerous GPCRs to activate several signaling pathways 
such as ERK (Table 3-1) (30-38). We have previously shown that PAR-responsive ERK 
activation is dependent on PAR-1 cross-activation of the EGFR in endothelial cells, and 
inhibiting ERK activation did not impact PAR-1-dependent NF-κB signaling (13). It has 
been reported that β-arrestins play a role in receptor cross-activation by some GPCRs 
through an interaction with Src (13,32). Similarly, we found that both β-arrestin 1-/- and β-
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arrestin 2-/- MEFs were unable to activate ERK signaling after thrombin challenge (Figure 
3-1). 
Given the great variability among GPCRs in their use of β-arrestins for signaling, 
we wanted to evaluate whether PAR-1 may differ from the LPA receptor and utilize β-
arrestin 1 to activate NF-κB signaling (Table 3-1). We used well-characterized β-arrestin 
1-/- MEFs and challenged them with thrombin to test the necessity of β-arrestin 1 in PAR-
1-dependent NF-κB signaling (23). Surprisingly, we demonstrated that β-arrestin 1 and 2 
are both required for PAR-1-dependent phosphorylation of IκBα after thrombin 
treatment. This is in contrast with the LPA receptor, which requires only β-arrestin 2 for 
NF-κB signaling (Figure 3-1). This illustrates a previously unknown essential role for both 
β-arrestins in PAR-1-dependent NF-κB signaling, and differentiates PAR-1 from LPA 
receptors in their mechanisms of NF-κB induction.  
Several GPCRs have biphasic activation of ERK signaling, with an early G 
protein phase that peaks at 5’ post-stimulation and a β-arrestin phase that peaks at 10’ 
post-stimulation of the receptor [40, 41]. Since PAR-1-dependent NF-κB signaling is 
known to be dependent on both G proteins and β-arrestins, we wanted to test for any 
possible biphasic characteristics in β-arrestin 1-/- MEFs. Even with longer time points, we 
still did not identify any induction of PAR-1-dependent NF-κB signaling in β-arrestin 1-/- 
MEFs (Figure 3-2). There do not appear to be independent G protein or β-arrestin 
phases to PAR-1-dependent NF-κB signaling, indicating that G proteins and β-arrestins 
work together to activate signaling (13,28).  
 
β-Arrestin 1’s role in thrombin-induced NF-κB signaling is to recruit parallel 
pathways that induce NF-κB signaling 
We next wanted to explore possible mechanisms to explain PAR-1 dependence 
on β-arrestin 1 in addition to β-arrestin 2’s interaction with the CBM complex. β-arrestin 1 
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has been reported to be a necessary scaffold protein in the PAR-1-activated PI3K/Akt 
signaling pathway in Chinese hamster embryo fibroblasts (39). We and others have 
shown that the PAR-1-dependent PI3K/Akt pathway modulates the activation of NF-κB 
signaling (Figure 2-4, 2-5) (13,26,28). We sought to explore whether either β-arrestin 1-/- 
or β-arrestin 2-/- MEFs would be unable to activate the PI3K/Akt pathway, which could 
explain their inability to activate the NF-κB pathway. Each MEF line was grown to near 
confluence alongside its respective wild-type control line, serum-starved and treated with 
thrombin. Cells were then lysed for western blot and evaluated for Akt and NF-κB 
activation. Interestingly, β-arrestin 2-/- MEFs maintained Akt activation while β-arrestin 1-/- 
MEFs lost their ability to activate Akt. Both cells were unable to activate the NF-κB 
pathway (Figure 3-1). 
  These results, along with our previously reported data that chemical inhibition of 
PI3K leads to a complete blockade of Akt and a partial blockade of IκBα 
phosphorylation, implicate Akt as partially responsible for the activation of the NF-κB 
pathway (Figure 2-4, 2-5). This provides a model for the role of PAR-1-dependent NF-κB 
signaling, in which each β-arrestin forms a separate but equally necessary signaling 
node with PAR-1. In this model, β-arrestin 2/CBM complex facilitates the 
polyubiquitination of IKKγ. In a parallel pathway, β-arrestin 1/PI3K/Akt contributes to NF-
κB signaling through a poorly defined mechanism.  
An additional kinase pathway that may co-regulate PAR-1 activation with the 
PI3K/Akt pathway is the RhoA/ROCK pathway. PAR-1 is known to signal via G proteins 
to activate the RhoA/ROCK pathway, which then induces actin cytoskeleton 
rearrangements (40,41). Additionally, RhoA/ROCK pathway-dependent actin 
cytoskeleton rearrangements, through an unclear mechanism, are required for NF-κB 
induction (42). Lastly, another GPCR, AGTR1, uses both β-arrestin 1 and Gαq/11 to 
initiate RhoA/ROCK-dependent permeability, while β-arrestin 2 functions independently 
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to activate ERK (43,44). These data are intriguing because they propose a model in 
which both β-arrestin 1 and G proteins work together to activate the RhoA/ROCK 
pathway similarly to PAR-1 activated NF-κB signaling, indicating that these pathways 
may be related.  
Based on the above, we sought to explore the concept that PAR-1 recruits β-
arrestin 1 to activate the RhoA/ROCK pathway. We found this pathway, along with the β-
arrestin 2/CBM complex, co-activates the NF-κB pathway in human and mouse 
endothelial cell lines. To do this, we used Y-27632, a specific chemical inhibitor of 
ROCK, which inhibits the kinase’s ability to bind ATP, thus blocking its activation (45). 
Endothelial cells were grown to confluence and then medium was changed to serum-
free twelve hours before inhibitor treatment. The inhibitor was added one hour before 
thrombin challenge and cell lysates were then collected for western blot. Y-27632-
inhibition of the ROCK pathway completely blocked the thrombin-induced 
phosphorylation of IκBα (Ser32/36) when compared to vehicle control (DMSO) in two 
distinct endothelial cell lines (Figure 3-3). The blockade of the RhoA/ROCK pathway was 
specific to the PAR-1-dependent NF-κB pathway, as PAR-1’s ability to activate the ERK 
signaling pathway was unaffected. This inhibition was not a general effect on all NF-κB 
signaling as TNFα induction of NF-κB remained unchanged (Figure 3-3). The most 
notable differences between PAR-1 and TNFα induction of the NF-κB pathway are 
related to how the IKK complex becomes activated; it seems probable that this is where 
the RhoA/ROCK pathway feeds into PAR-1-dependent NF-κB activation. 
These data, when taken together, reveal a possible mechanism for both β-
arrestins in PAR-1-dependent NF-κB signaling (Figure 3-4). Both β-arrestin 1 and β-
arrestin 2 are recruited to thrombin stimulated PAR-1, then act as independent signaling 
nodes to recruit their own signaling pathways which feed into NF-κB activation. β-
arrestin 2 is established as being necessary for the recruitment of CARMA3 to the 
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receptor, leading IKKγ to activate ubiquitination by the CBM/TRAF6 complex. β-arrestin 
1 acts as a node for two kinase pathways, PI3K/Akt and RhoA/ROCK. Each of these 
pathways can alter NF-κB induction, possibly through the phosphorylation of IKKβ, which 
is known to be independent of β-arrestin 2 (14). Both polyubiquitination and 
phosphorylation of the IKK complex are needed for NF-κB activation. The loss of either 
β-arrestin would thus disrupt NF-κB activation (Figure 3-4).  
 
The hunt for the GRK necessary for arrestin recruitment to PAR-1 
G protein receptor kinases (GRKs) are a seven-member family of 
serine/threonine kinases. GRKs phosphorylate the C-terminal tail of ligand-activated 
GPCRs, and recruit β-arrestins to the receptor for desensitization and signaling (46). 
GRKs are categorized into three subfamilies based on homology: the GRK1 subfamily 
includes GRK1 and GRK7, the GRK2 subfamily includes GRK2 and GRK3, and the 
GRK4 subfamily includes GRK4, GRK5 and GRK6. GRK1, GRK7 and GRK4 have 
restricted tissue expression, but the remaining GRKs are ubiquitously expressed, 
including in endothelial cells (46-48). Structurally, GRKs share a highly conserved kinase 
domain in the center. The N-terminus of the enzyme contains protein-binding domains 
for substrate specificity and kinase regulation while the C-terminus is needed for 
membrane localization (47). Having characterized a necessary role for β-arrestin 1 and 
β-arrestin 2 for PAR-1-dependent NF-κB signaling, we sought to next identify the GRKs 
that are required for the recruitment of β-arrestins to PAR-1.  
We hypothesized that depleting the endothelial cells of the GRKs needed for 
PAR-1 phosphorylation would inhibit β-arrestin recruitment and thus block PAR-1-
dependent NF-κB signaling. We started with GRK2 as it is the best functionally defined 
GRK and is known to be expressed in endothelial cells (48). To test this, we used GRK2-
specific siRNA to knockdown GRK2 expression in the endothelial cell cultures for 36 
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hours followed by 12 hours of serum-free media before treatment with thrombin. 
Western blot showed that GRK2 siRNA treatment of endothelial cell cultures caused the 
depletion of GRK2 proteins after transfection, while the GRK2 levels of control siRNA-
treated cells remained unaffected. Surprisingly, knocking down GRK2 had the opposite 
effect on PAR-1-dependent NF-κB activation in endothelial cells from what we had 
hypothesized (Figure 3-5). GRK2 knockdown caused a notable increase in the level of 
phosphorylation of IκBα (Ser32/36) after thrombin challenge, indicating an increase in the 
activation of the NF-κB pathway. The effect of increasing phosphorylation of IκBα with 
GRK2 depletion was specific to PAR-1-dependent NF-κB activation, as IL-1β induction 
of the NF-κB pathway did not increase. This is the first report to demonstrate that GRK2 
can act as a negative regulator of the GPCR-dependent canonical NF-κB signaling 
pathway.  
Several in vivo models of endothelial dysfunction demonstrate that both GRK2 
expression levels and kinase activity were increased versus normal control. GRK2 was 
able to co-immunoprecipitate with Akt and this was associated with reduced Akt activity. 
Loss of Akt activity resulted in the reduction of nitric oxide production, which contributed 
to endothelial dysfunction (48,49). We theorized that GRK2’s negative regulation of Akt 
activity could, in turn, down-regulate NF-κB signaling. We then performed western blots 
for three signaling pathways that we previously established as being dependent on PAR-
1 activation: NF-κB, ERK and Akt. The western blot for phosphorylation of Akt (Ser473), 
as we predicted, showed an increase in the activation of the Akt protein (Figure 3-5). 
Meanwhile, phosphorylation of ERK remained unaffected, thereby displaying specificity 
to this pathway. Correlative increases in both the phosphorylation of Akt and IκBα added 
to speculation that the increased NF-κB activation is at least partly due to an increase in 
the PI3K/Akt pathway (13,28).  
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GRK2 regulates PAR-1-dependent NF-κB transcriptional activity and gene 
expression 
Having defined GRK2 as a negative regulator of the NF-κB pathway at the 
upstream cytosolic point of the phosphorylation of IκBα, we sought to measure the effect 
of GRK2 depletion in the terminal steps of the NF-κB pathway. We used an endothelial 
cell line stably transfected with an NF-κB reporter plasmid to gauge the effect of 
transient GRK2 depletion on the transcription potential of the NF-κB pathway. These 
cells were transfected with GRK2-specific siRNA or control for 36 hours and then 
changed to serum-free media for an additional 12 hours. GRK2 depletion resulted in an 
increase in NF-κB transcriptional potential after thrombin treatment (Figure 3-6). This 
increase in transcriptional activity was specific to thrombin stimulation of the NF-κB 
pathway, as IL-1β activation of NF-κB transcription did not change. 
  In a similar experiment, NF-κB reporter plasmids were co-transfected with a 
construct expressing wild-type GRK2 to test if overexpressing the GRK2 proteins in 
endothelial cells could inhibit PAR-1-dependent NF-κB activation. Results showed a 
40% decrease specific to thrombin activation of the NF-κB transcriptional potential, as 
IL-1β activation of NF-κB remained relatively unchanged (Figure 3-7). GRK2-specific 
regulation of thrombin-dependent but not IL-1β-dependent NF-κB signaling indicates that 
GRK2 is likely to be involved upstream of where these two receptor pathways meet at 
the IKK complex.  
We have previously published that thrombin can stimulate VCAM-1 expression 
through PAR-1-dependent CBM complex activation of the NF-κB signaling pathway in 
endothelial cells (13). VCAM-1 binds to mononuclear leukocytes, particularly monocytes, 
when expressed on inflamed endothelial cells, which contributes significantly to 
endothelial dysfunction (50). We tested whether the increases in phosphorylation of IκBα 
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and activation of the NF-κB reporter plasmid seen in GRK2-depleted cells would also 
correspond with an increase in NF-κB-dependent gene expression. We used GRK2 and 
control siRNA to knock down GRK2 expression in endothelial cells for 36 hours, then put 
the cultures in serum-free media overnight. The next day, cells were challenged with 
thrombin for either four or six hours to test the effects of GRK2 depletion on the ability of 
endothelial cells to up-regulate VCAM-1 expression. Thrombin treatment induced 
VCAM-1 expression in control siRNA-treated endothelial cells at both time points, but 
GRK2 depletion caused a more robust induction of VCAM-1 at both time points (Figure 
3-8). 
This demonstrates that GRK2 can down-regulate PAR-1-dependent gene 
expression and GRK2 may help to protect the endothelium from the pro-atherogenic 
effects of GPCR-dependent NF-κB activation. Thus, it appears that the reported 
increases in GRK2 expression levels of dysfunctional endothelium may act as a double-
edged sword: increased GRK2 may reduce Akt-dependent vascular relaxation, a pro-
endothelial dysfunction property, but also down-regulate GPCR-dependent NF-κB 
activation, an anti-endothelial dysfunction property. This, therefore, complicates 
speculation that GRK2 would make a good pharmaceutical target in endothelial 
dysfunction (48,49). Future studies on the effects of GRK2 in endothelial dysfunction 
should be broadened to include multiple signaling pathways besides Akt and additional 
endothelial properties besides relaxation. This would enable us to better understand the 
total impact of GRK2 in the endothelium. 
 
 
Discussion 
Thrombin activation of PAR-1 induces the NF-κB signaling pathway in endothelial 
cells which contributes to atherogenesis by modulating gene expression, endothelial 
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permeability, and vascular tone. Here we provide evidence for the complex roles of β-
arrestin and the GRKs in regulation of PAR-1-dependent NF-κB signaling. In an 
apparent difference with the LPA receptor, we reported here that PAR-1-dependent NF-
κB stimulation was inhibited with a loss of either β-arrestin 1 or β-arrestin 2. This led us 
to define a previously unknown role for β-arrestin 1 in PAR-1 induction of the NF-κB 
pathway. We then searched the literature for signaling pathways that had the following 
criteria: 1) activation by a GPCR in a β-arrestin 1-dependent fashion and 2) modulation 
of the NF-κB signaling pathway at a point before IκBα phosphorylation. We identified two 
kinase pathways, the PI3K/Akt and RhoA/ROCK pathways, that fit this criteria 
(28,39,51,52).  
The PI3K/Akt pathway has been illustrated to participate in PAR-1-dependent 
NF-κB signaling (13,25,28). We previously explored the possible role of PI3K/Akt in 
PAR-1-dependent NF-κB signaling and found that blocking Akt activation correlated with 
a reduction of phosphorylation of IκBα. Phosphorylation of IκBα was never completely 
blocked with Akt inhibition, possibly pointing to the involvement of an additional pathway 
for NF-κB activation. (Figure 2-4, 2-5) (13). These data, along with the fact that some 
GPCRs use β-arrestin 1 to activate Akt signaling, made us wonder what impact the loss 
of β-arrestins would have on PAR-1-dependent Akt. PAR-1-dependent Akt activation 
was blocked in the β-arrestin 1-/- MEFs but was still functional in β-arrestin 2-/- MEFs. This 
points to the parallel pathways of the β-arrestin 1/PI3K/Akt and β-arrestin 2/CBM 
complexes, which merge to facilitate PAR-1-dependent NF-κB activation.  
The RhoA/ROCK pathway relies on β-arrestin 1 and G protein activation, and 
has been implicated in NF-κB induction through an unclear mechanism (51,52). These 
data, in which both β-arrestin 1 and G proteins work together to activate the 
RhoA/ROCK pathway, suggest a mechanism similar to one that PAR-1 uses to activate 
NF-κB signaling, indicating that these pathways could be interdependent. Using a 
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ROCK-specific chemical inhibitor, we demonstrated a complete blockade of NF-κB 
activation after thrombin challenge. We demonstrated that both β-arrestin 1 and 
activation of ROCK are necessary for PAR-1-dependent NF-κB signaling, raising the 
possibility that β-arrestin 1 and RhoA/ROCK operate in a single pathway parallel to the 
β-arrestin 2/CBM complex pathway. However, further testing is needed to validate this 
fully.  
GRKs are a family of serine/threonine kinases that phosphorylate the ligand-
activated GPCR and recruit β-arrestins that both desensitize the receptor and induce 
signaling pathways [65]. Having established the necessity of β-arrestin 1 and β-arrestin 
2 for PAR-1-dependent NF-κB signaling, we sought to determine which GRKs were 
required for NF-κB induction. Instead, we discovered that GRK2 negatively regulated 
PAR-1-dependent NF-κB signaling. When GRK2 was depleted, we observed an 
increase in PAR-1-dependent NF-κB signaling which did not affect IL-1β-dependent NF-
κB signaling. This increase in PAR-1-dependent NF-κB activity resulted in increased 
expression of VCAM-1, a mediator of endothelial dysfunction. We are the first to 
establish that GRK2 is negatively regulating GPCR-dependent canonical NF-κB 
signaling.  
GRK2 is a recognized negative regulator of the Akt pathway. In endothelial 
dysfunction, increases in GRK2 were linked with decreased Akt function. This inhibition 
in Akt activation blocked NO production, which contributes to endothelial dysfunction 
(48,49). We hypothesized that GRK2’s negative regulation of Akt activity could, in turn, 
down-regulate NF-κB induction. Depletion of GRK2 caused an increase in 
phosphorylation of both Akt and IκBα, providing evidence that these pathways are both 
regulated by GRK2. This data, combined with our results that loss of β-arrestin 1 and 
chemical inhibition of PI3K inhibit both NF-κB and Akt activation, makes a strong 
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circumstantial argument that these pathways are interdependent, with Akt activation 
needed for PAR-1-dependent NF-κB signaling (Figure 3-9). 
Additionally, it is interesting to note that several studies on the role of GRK2 in 
endothelial dysfunction concluded that GRK2 was an ideal drug candidate since GRK2 
inhibited Akt-regulated NO production, which leads to a loss of vascular tone regulation. 
While they showed an improvement in vascular tone with an inhibitor or RNAi 
knockdown of the GRK2 in the endothelium, they did not address the effects on pro-
endothelial dysfunction NF-κB signaling or other endothelial phenotypes (48,49). Our 
data show that inhibition of GRK2 leads to an increase in NF-κB activation and cell 
adhesion molecule expression, both of which are classic markers of endothelial 
dysfunction. These effects induced by GRK2 inhibition should be weighed when 
considering GRK2 as a pharmaceutical target for treatment of endothelial dysfunction.  
An alternative or additional potential model for how GRKs and β-arrestins can 
both induce and inhibit GPCR-dependent NF-κB signaling comes from multiple studies 
of how different GPCRs activate the ERK pathway (53-58). ERK activation is biphasic, 
consisting of an overlapping G protein-dependent early phase and a β-arrestin-
dependent late phase. In several studies, knockdown of GRK2 family members caused 
a significant increase in the G protein-dependent phase of ERK signaling, which is 
consistent with GRK2’s role of uncoupling G proteins, and this increase lasted through 
the β-arrestin-dependent phase. These results were strikingly similar to our PAR-1-
dependent NF-κB activation in GRK2-depleted cells, possibly indicating that GRK2 is 
involved in the uncoupling of the G proteins needed for PAR-1-dependent NF-κB 
activation.  
Next, researchers evaluated the role of GRK4 family members in GPCR-
dependent ERK activation. Knockdown of GRK4 family members resulted in the 
reduction of later β-arrestin phases of ERK activation and, when combined with a 
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general inhibitor of PKC, which is activated by the G protein phase, all activation was 
completely blocked. This illustrates that the GRK4 family is responsible for the β-arrestin 
recruitment that leads to signaling and not to desensitization. Also, both G protein- and 
β-arrestin-dependent signaling work together for the activation of the ERK pathway in 
certain GPCRs. This is similar to the need for both β-arrestins and G proteins for the co-
activation of PAR-1-dependent NF-ĸB signaling by the β-arrestin 1/ROCK, β-
arrestin1/Akt and β-arrestin 2/CBM complex pathways in conjunction with G protein 
activation (52,56,58). 
Interestingly, it was discovered that only the GRK2 subfamily was responsible for 
signal terminating receptor internalization and only the GRK5 subfamily was responsible 
for ERK signaling despite both subfamilies participating in GPCR phosphorylation and β-
arrestin recruitment (56,58). The authors theorize that the functional differences between 
the GRK subfamilies could be due to still unknown variances in their phosphorylation 
sites on the receptor. These differences may form a phosphorylation “bar code” which is 
read by the β-arrestins, causing them to take on different conformational changes 
depending on which GRK’s phosphorylation they are binding to. This would allow β-
arrestins to either induce internalization to end signaling or act as scaffolds for signaling 
(56,58). In support of this, it has been shown that β-arrestin 1 and β-arrestin 2 do take 
on different active conformations when bound to phosphorylated GPCRs (59).  
Building upon our β-arrestin model and our GRK2 data, a possible hypothesis for 
PAR-1/β-arrestin-dependent NF-κB signaling is that GRK2 subfamily members are 
responsible for the signal terminating phosphorylation that desensitizes PAR-1 (Figure 3-
9). This would lead to the recruitment of β-arrestin in a conformation that terminates G 
protein signaling and thus down-regulates NF-κB signaling. In contrast, GRK4 subfamily 
members would be responsible for the phosphorylation of PAR-1 and recruitment of β-
arrestins in a conformation needed for signaling nodes as described above. How the 
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GRK2 subfamily and GRK4 subfamily differently phosphorylate GPCRs remains an 
important but unclear mechanism.  
 In summary, we show that multiple parallel pathways connect PAR-1 to the 
activation of the NF-κB pathway, in addition to the CBM complex which we previously 
reported. These parallel pathways originate from the recruitment of β-arrestins by GRK-
mediated phosphorylation of the receptor. β-arrestin 2 serves as the node for the CBM 
complex which leads to IKK complex polyubiquitination. In addition, we theorize that β-
arrestin 1 serves as a node to the activation of the RhoA/ROCK and PI3K/Akt pathways. 
These co-stimulate the NF-κB pathway, possibly contributing to the phosphorylation of 
the IKK complex. Lastly, based on our data and the literature, GRK2 and GRK4 
subfamily members may work in opposition to each other, potentially due to the fact that 
their different target phosphorylation sites alter β-arrestin function (56,58). GRK2 is now 
identified as a negative regulator of PAR-1-dependent NF-κB activation through receptor 
desensitization and/or by inhibiting Akt’s ability to participate in NF-κB signaling. All of 
these pathways represent additional complex levels of PAR-1- dependent NF-κB 
activation. This level of complexity might be needed to control the powerful NF-κB 
pathway from causing endothelial dysfunction, yet still allowing the endothelium the 
flexibility to respond to various stimuli properly. This work provides us with additional 
insights into the complex mechanism that initiates and terminates PAR-1-dependent NF-
κB signaling.  
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A. 
B. 
Figure 3-1. Loss of either β-arrestin 1 or β-arrestin 2 inhibits PAR-1-dependent 
NF-κB signaling. β-arrestin 1 knock-out, β-arrestin 2 knock-out and their matched 
wild-type MEFs were treated with thrombin for the indicated periods of time or with 
TNFα for 5 min. The cells were harvested and analyzed for IκBα phosphorylation. The 
results demonstrated that wild-type MEFs respond to both thrombin and TNFα with p-
IκBα generation, but both β-arrestin 1 and β-arrestin 2 knock-out (KO) MEFs are 
completely unresponsive to thrombin while they maintain their responsiveness to 
TNFα. Wild-type MEFs respond to thrombin with p-Akt generation, while β-arrestin 2 
knock-out MEFs maintained p-Akt generation and β-arrestin 1 knock-out MEFs are 
unresponsive to thrombin-dependent Akt signaling. Meanwhile, wild-type MEFs 
respond to thrombin with p-ERK generation, but both β-arrestin 1 and β-arrestin 2 
knock-out MEFs are unresponsive to thrombin for ERK signaling. 
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Figure 3-2. PAR-1-dependent NF-κB signaling is through a single phase of 
activation. β-arrestin 1 knock-out and their matched wild-type MEFs were treated 
with thrombin for the indicated periods of time. The cells were harvested and 
analyzed for IκBα phosphorylation. The results demonstrated that wild-type MEFs 
respond to thrombin with p-IκBα generation which peaked between 10-15’ and then 
tapers off. Meanwhile, β-arrestin 1 knock-out MEFs are completely unresponsive to 
thrombin, demonstrating induction consists of a single phase of induction which was 
totally dependent on arrestin activity. 
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Figure 3-3. Thrombin-induced NF-κB signaling is dependent on RhoA/ROCK 
activation. A, SVEC4–10 mouse endothelial cells were pretreated for 1 hour with 
dimethyl sulfoxide (DMSO) vehicle or with 10 M Y-27632, a specific chemical 
inhibitor of ROCK. The cells were then treated with thrombin for the indicated periods 
of time. The cells were harvested and analyzed by western blotting with the indicated 
antibodies. The inhibitor had a significant effect on thrombin-dependent 
phosphorylation of IκBα. As expected, TNFα-dependent IκBα phosphorylation and 
thrombin-dependent ERK phosphorylation were not affected by Y-27632, showing 
specificity for the effects of the inhibitor at the10 M dose. B, EA.hy926, human 
endothelial cells, were treated the same as in 3-3A. The inhibitor had a significant 
inhibition of thrombin-dependent phosphorylation of IκBα, showing that this is a 
common pathway of PAR-1 signaling across species. Please note that the DMSO 
and Y-27632 wells are reversed compared to figure 3-3A. 
A. 
  
Figure 3-1. Loss of either β-arrestin 1 or β-arrestin 2 inhibits PAR-1-dependent NF-κB. A, β-
arrestin 1 knock-out, B, β-arrestin 2 knock-out and their matched wild-type MEFs were 
treated with thrombin for the indicated periods of time or with TNFα for 5 min. The cells 
were harvested and analyzed for IκBα phosphorylation. The results demonstrated that wild-
type MEFs respond to both thrombin and TNFα with p-IκBα generation, but both β-arrestin 1 
and β-arrestin 2 knock-out (KO) MEFs are completely unresponsive to thrombin while they 
maintain their responsiveness to TNFα. Wild-type MEFs respond to thrombin with p-Akt 
generation, while β-arrestin 2 knock-out maintained p-Akt generation and β-arrestin 1 knock-
out MEFs are unresponsive to thrombin-dependent Akt signaling. Meanwhile, wild-type 
MEFs respond to thrombin with p-ERK generation, but both β-arrestin 1 and β-arrestin 2 
knock-out MEFs are unresponsive to thrombin for ERK signaling. 
B. 
  
Figure 3-1. Loss of either β-arrestin 1 or β-arrestin 2 inhibits PAR-1-dependent NF-κB. A, β-
arrestin 1 knock-out, B, β-arrestin 2 knock-out and their matched wild-type MEFs were 
treated with thrombin for the indicated periods of time or with TNFα for 5 min. The cells 
were harvested and analyzed for IκBα phosphorylation. The results demonstrated that wild-
type MEFs respond to both thrombin and TNFα with p-IκBα generation, but both β-arrestin 1 
and β-arrestin 2 knock-out (KO) MEFs are completely unresponsive to thrombin while they 
maintain their responsiveness to TNFα. Wild-type MEFs respond to thrombin with p-Akt 
generation, while β-arrestin 2 knock-out maintained p-Akt generation and β-arrestin 1 knock-
out MEFs are unresponsive to thrombin-dependent Akt signaling. Meanwhile, wild-type 
MEFs respond to thrombin with p-ERK generation, but both β-arrestin 1 and β-arrestin 2 
knock-out MEFs are unresponsive to thrombin for ERK signaling. 
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Figure 3-4. A role for both β-arrestin 1 and β-arrestin 2 in PAR-1-dependent 
NF-κB signaling. Both β-arrestin 1 and β-arrestin 2 are recruited by thrombin-
activated PAR-1, then act as independent signaling nodes to recruit their own 
signaling pathways which input into NF-κB activation. β-arrestin 2 is recognized as 
being necessary for the recruitment of CARMA3 to the receptor, leading to IKKγ 
activating ubiquitination by the CBM/TRAF6 complex. β-arrestin 1 acts as a node 
for two kinase pathways, PI3K/Akt and RhoA/ROCK. Each of these pathways can 
alter NF-κB induction, possibly through the phosphorylation of IKKβ, which is known 
to be independent of β-arrestin 2/CBM complex activity. Both polyubiquitination and 
phosphorylation of the IKK complex are needed for NF-κB activation. The loss of 
either β-arrestin disrupts NF-κB activation by thrombin-stimulated PAR-1. 
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Figure 3-5. GRK2 is an inhibitor of PAR-1-dependent NF-κB and Akt signaling. 
SVEC4–10 cells were transfected with siRNA pools targeting GRK2, designed by 
Dharmacon at a concentration of 10nM. 48 hours following transfection, the cells 
were treated with thrombin for the indicated periods of time. The cells were harvested 
and analyzed by western blotting with the indicated antibodies. GRK2 knockdown 
increased both p-IκBα and p-Akt generation following thrombin treatment. The impact 
of GRK2 on thrombin signaling was specific to the canonical NF-κB and Akt 
pathways, because GRK2 knockdown had no effect on the ability of thrombin to 
induce p-ERK. GAPDH was used as a loading control. 
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Figure 3-6. GRK2 knockdown increases thrombin-responsive NF-KB reporter 
activity. SVEC4–10 endothelial cells stably expressing the NF-κB-luciferase reporter 
were transfected with either a control siRNA pool or with a siRNA pool targeting 
GRK2. After 48 hours, the cells were treated for another 5 hours with either thrombin 
(5U/ml) or IL-1β (0.125ng/ml). The cells were harvested and NF-κB induction was 
evaluated by measuring luciferase levels, corrected for cell number. The outcomes 
indicated that GRK2 knockdown increased NF-κB activation by thrombin but had no 
effect on the activation achieved with IL-1β. This result is representative of three 
independent experiments. 
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Figure 3-7. GRK2 overexpression decreases thrombin-responsive NF-KB 
reporter activity. SVEC4-10 cells were co-transfected with NF-κB-luciferase and 
control Renilla reporter plasmids, and either GRK2 expression vector or empty vector 
control. The cells were then stimulated for 5 hours with or without thrombin. The cells 
were harvested, and the subsequent NF-κB induction was measured by calculating 
the luciferase/Renilla ratio. GRK2 overexpression was able to block thrombin-induced 
NF-κB activation under these conditions. The results are expressed as percentage 
inhibition of fold NF-κB induction. 
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Figure 3-8. GRK2 knockdown increases thrombin-dependent induction of 
cellular adhesion molecules. SVEC4-10 cells were transfected with control or 
GRK2 siRNA and allowed to recover for 48 hours. The cells were then treated with 
thrombin for the indicated periods of time before harvest and western analysis. GRK2 
knockdown not only increased NF-κB signaling but also increased expression of an 
NF-κB responsive gene, VCAM-1. 
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Figure 3-9. A role for G protein receptor kinases in the regulation of PAR-1 
signaling. The role of GRK2 in the inhibition of PAR-1-dependent NF-κB 
signaling could occur through the down-regulation of Akt kinase activity that 
would reduce the phosphorylation of the IKK complex. An additional or alternative 
mechanism for GRK2 inhibition of PAR-1-dependent NF-κB signaling may be 
caused by desensitizing phosphorylation of PAR-1. This would lead to the 
recruitment of β- arrestins in a conformation that terminates G protein signaling 
and causes receptor internalization, thus down-regulating NF-κB activation. 
GRK5 subfamily members may be responsible for the phosphorylation of PAR-1 
that recruits β-arrestins in a conformation to act as signaling nodes. In this model 
GRK5 and GRK2 subfamilies are opposing forces in PAR-1-dependent signaling. 
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GPCR Pathway β-Arrestin  Reference 
Adenosine A 1 receptor ERK, JNK β-arrestin 1 (56) 
Ang II type 1 receptors ERK, JNK β-arrestin 2 (60,61) 
β2-adrenergic receptor ERK β-arrestin 1 (62) (63) 
Growth hormone secretagogue 
receptor type 1a 
ERK β-arrestin 1 and 
2 
(34) 
Metabotropic glutamate 
receptor 1 
ERK β-arrestin 1 (33) 
Parathyroid hormone type 1 
receptor 
ERK β-arrestin 1 and 
2 
(54) (37) 
Prostaglandin E2 receptor Akt, ERK, 
STAT3, JNK 
β-arrestin 1 (32,64) 
Protease-activated receptor-1 Akt, NF-κB β-arrestin 1, β-
arrestin 2 
(13,65) 
Protease-activated receptor-2 ERK β-arrestin 1 and 
2 
(38) 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-1. The requirement of β-arrestins for GPCR-dependent cell signaling. 
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Chapter IV 
 
Summary and Future Directions 
 
Summary of Results 
There is a pressing need globally to understand the molecular mechanisms of 
cardiovascular disease as it is the leading cause of disease-related deaths in the world 
(1). Atherosclerotic plaques narrow the vessel lumen, decreasing blood flow to the  
organs, and plaque rupture can result in thrombosis, causing stroke or myocardial 
infarction (Figure 1-3) (2). Atherosclerosis is a chronic inflammation of the vasculature in 
which the pro-inflammatory pathway, NF-κB, is a chief driving force (3,4). NF-κB-
dependent plaque formation is mediated via the expression of cytokines, chemokines 
and CAMs by the dysfunctional endothelium, causing leukocyte recruitment and VSMC 
proliferation (Figure 1-1, 1-3) (4).  
GPCRs have been implicated as mediators of endothelial dysfunction for a 
number of diseases such as atherosclerosis, diabetes and infectious diseases (5-7). 
While it was known that GPCRs were facilitating atherosclerosis via NF-κB signaling, 
little was known prior to our work about the molecular mechanism of this signaling (8,9). 
The purpose of this work has been to expand our understanding of the regulation of 
GPCR-dependent NF-κB signaling in endothelial dysfunction through the use of PAR-1 
and AGTR1 as models with the expectation that this will lead to the development of 
novel treatments for atherosclerosis and other inflammatory diseases (Figure 4-1). 
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Protease Activated Receptor-1 is a player in endothelial dysfunction 
Here we explored PAR-1’s signaling pathways, their regulation, and phenotypic 
effects as a model for GPCR-dependent endothelial dysfunction. PAR-1 is a major 
participant in atherogenesis, regulating cell gene expression, endothelial permeability, 
and vascular tone (6,10). We demonstrated for the first time that PAR-1 activates ERK, 
Akt, and NF-κB signaling pathways in SVEC4-10, an immortalized mouse endothelial 
cell line (Figure 2-1, 2-3). These results are consistent with previously published data 
from HUVEC, a primary endothelial cell line (11,12). The robust and consistent nature of 
PAR-1-dependent signaling in SVEC4-10 cells makes them an ideal cell model to test 
the mechanisms of GPCR signaling and the effects of PAR-1 in endothelial biology.  
Until recently, GPCR-dependent canonical NF-κB signaling was poorly defined 
(Figure 1-2). However, it was noted by our group and others to have a key similarity with 
T-cell receptor-dependent CARMA1/Bcl10/MALT1 complex-induced NF-κB signaling: 
dependence on PKC activation (Figure 1-4) (13,14). This led us to discover that the 
CARMA3/Bcl10/MALT1 complex was required for GPCR-dependent NF-κB signaling 
through the activation of PKCs and G proteins (Figure 1-6) (13-15). Prior to our work, 
Rahman et al. and Minami et al. reported that thrombin treatment of HUVEC led to PAR-
1-dependent p65 nuclear localization and NF-κB-regulated gene transcription in a PKC-, 
G protein- and PI3K-dependent manner. But they did not elucidate the intermediate 
steps between receptor proximal events and the phosphorylation of IκBα (Figure 1-2) 
(11,12).  
We sought to bridge this critical gap in PAR-1 biology, and established that the 
CBM complex is necessary for PAR-1-dependent NF-κB activation (Figure 2-2). This 
finding is particularly exciting in the larger context of NF-κB-dependent atherogenesis, as 
we also demonstrated that AGTR1 uses the CBM complex to induce atherogenesis in 
vivo (Figure 2-9) (9). Our in vitro studies found similar potential for atherogenesis by 
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PAR-1 activation of the CBM complex, as its disruption inhibited thrombin-induced CAM 
expression (Figure 2-7), and reduced the adhesion of monocytes to the endothelial cell 
(Figure 2-8). This resulted in the disruption of a key step in plaque progression. It now 
appears that the CBM complex is at the crossroads of multiple GPCRs that contribute to 
atherogenesis (Figure 4-1). It is our belief that GPCRs involved in inflammatory diseases 
are likely to use CBM complex-dependent NF-κB signaling to advance the disease. 
Therefore, understanding the mechanisms of this protein complex is key to 
understanding inflammatory disease progression and potential treatments. 
 
Differences in GPCR and T-cell receptor CBM complex recruitment  
Once we established that PAR-1 signals through the CBM complex, we sought to 
use PAR-1 to compare regulation of the CBM complex by GPCRs to that of the well-
defined regulation by the T-cell receptor. The activation of the T-cell receptor stimulates 
PI3K, which recruits PDK1 that serves as a scaffold for both PKCθ and CARMA1 (Figure 
1-4) (16). It has been previously reported that PAR-1-dependent NF-κB activation is 
reliant on both PI3K and PKC, making PAR-1 an attractive model to test if CARMA3 is 
also recruited to the receptor by PDK1 (Figure 1-6) (12,17). Through co-
immunoprecipitation, we were able to show that CARMA3 could bind to PDK1 when co-
expressed in 293T cells (Figure 2-3). Based on the ability of exogenously expressed 
Carma3 to rescue T-cell receptor-dependent NF-κB signaling in Carma1-/- MEFs, this 
was the predicted result (18,19).  
Despite this, the PDK1-CARMA3 interaction had no biological consequences 
within the context of PAR-1-dependent NF-κB activation, as depletion of PDK1 did not 
inhibit signaling (Figure 2-4). This is the first demonstrated difference between GPCR- 
and T-cell receptor activation of the CBM complex. In many ways, this is not surprising 
since the potential differences between GPCR- and T-cell receptor-dependent CBM 
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complexes recruitment start with 53% amino acid sequence differences between the 
CARMAs. Additionally, the receptors themselves and the pathways that they stimulate 
significantly differ. Understanding the differences between how these different receptor 
families interact with their respective CBM complexes will provide insight into how each 
complex functions (Figure 1-6). These differences may prove invaluable for the 
development of pharmaceutical inhibition of CBM complex recruitment where it could be 
advantageous to inhibit the ability of one receptor family to activate the CBM complex 
over the other for disease treatment. Certainly future studies should continue to 
investigate differences between how these receptors activate the CBM complex. 
β-arrestin 1 and β-arrestin 2 act as scaffold proteins for GPCR-dependent cell 
signaling (Table 3-1) (20). Sun et al. illustrated that β-arrestin 2 binds to CARMA3 to act 
as a bridge to the active LPA receptor for NF-κB signaling while β-arrestin 1 was 
dispensable for this (21). Our PAR-1-dependent NF-κB signaling results agree, showing 
that β-arrestin 2-/- MEFs were defective in thrombin-dependent NF-κB signaling (Figure 
2-4, 3-1). Thus, the role of β-arrestin 2 in GPCR signaling appears to be analogous to 
the role of PDK1 in the T-cell receptor recruitment of CARMA1 (Figure 2-10). It is 
interesting to speculate that β-arrestin 2 may bind to PKCs to orientate them to 
phosphorylate CARMA3 since PDK1 does this in CARMA1 recruitment (22). 
We demonstrated a previously unknown critical role for β-arrestin 1 in PAR-1-
dependent NF-κB signaling (Figure 3-1), which differentiates PAR-1 from LPA receptor-
dependent NF-κB activation. To understand the role of β-arrestin 1 in PAR-1-dependent 
NF-κB signaling, we focused on published differences between the mechanisms of LPA 
receptor- versus PAR-1-dependent NF-κB signaling. LPA receptor-dependent NF-κB 
activation required two separate parallel pathways that merged at the IKK complex for 
NF-κB activation: the β-arrestin 2/CBM complex for polyubiquitination and the MEKK3 
pathway for phosphorylation of the IKK complex (21,23). We searched for kinase 
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pathways that are implicated in GPCR-dependent NF-κB signaling and whose 
components are recruited to GPCRs by β-arrestin 1.  
  The RhoA/ROCK and PI3K/Akt kinase pathways have been implicated in GPCR-
dependent NF-κB activation and have been shown to require β-arrestin 1 for their 
activation by GPCRs (Figure 3-4) (17,24-26). While both of these pathways have been 
demonstrated to modulate PAR-1-dependent NF-κB signaling, how they do this remains 
largely unknown. A possible mechanism for how both these pathways modulate PAR-1-
dependent NF-κB signaling comes from research into IL-1β-dependent NF-κB activation, 
in which IL-1β-activated Akt and ROCK were able to phosphorylate the IKK complex 
(27,28). Similarly, we found that both the PI3K/Akt (Figure 2-4, 2-5) and RhoA/ROCK 
(Figure 3-3) kinase pathways function downstream of PAR-1 to activate NF-κB signaling. 
Additionally, Watts et al. show PAR-1-dependent RhoA/ROCK activation down regulates 
the activity of eNOS and thus NO levels, and others have demonstrated that NO is an 
inhibitor of NF-κB signaling (29-31). Thus, we believe that β-arrestin 1 acts as a parallel 
signaling node to the β-arrestin 2/CBM complex to activate both the PI3K/Akt and 
RhoA/ROCK pathways. These two pathways are necessary for activation of the NF-κB 
pathway, possibly through the phosphorylation of the IKK complex and/or, in the case of 
ROCK, by reducing the NO levels in the cell (Figure 4-2). A possible reason for the need 
for multiple parallel pathways for the activation of NF-κB signaling may be to allow the 
GPCRs to fine tune the induction of the NF-κB pathway. The differences in these parallel 
pathways between GPCRs may allow them to individualize their induction of NF-κB 
signaling with respect to their biological function in the cell. 
 
GRK2: a novel regulator of PAR-1-dependent NF-κB signaling 
GRKs are a family of serine/threonine kinases which phosphorylate ligand-
activated GPCRs to recruit β-arrestins (32). We hypothesized that GRKs are positive 
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regulators of PAR-1-dependent NF-κB signaling via their recruitment of β-arrestins to 
GPCRs. To our surprise, GRK2 depletion noticeably increased the ability of thrombin to 
activate NF-κB signaling (Figure 3-5, 3-6). This effect was specific to PAR-1-dependent 
NF-κB signaling, as the IL-1β-dependent NF-κB pathways did not increase. This is the 
first report of GRK2 as a negative regulator of the GPCR-dependent canonical NF-κB 
pathway. 
Our results are analogous to the role of GRKs in GPCR-dependent ERK 
activation, in which depletion of GRK2 family members caused an increase in ERK 
signaling, due to a loss of G protein uncoupling by GRK2. This increase in G protein 
activation could cause the change in NF-κB signaling we observed. Another possible 
mechanism for GRK2-mediated negative regulation of PAR-1-dependent NF-κB 
signaling may be in GRK2’s ability to bind to Akt (Figure 4-2). Studies have shown that 
depletion of GRK2 results in an increase in Akt phosphorylation and kinase activity 
(33,34). Given that PI3K/Akt signaling modulates PAR-1-dependent NF-κB signaling, we 
predicted that the increase in NF-κB activation may be due to an increase in Akt kinase 
activity in the absence of GRK2. Depletion of GRK2 leads to an increase in the 
phosphorylation of both Akt and IκBα after thrombin challenge (Figure 3-5). While this 
data is correlative, based on the literature, we believe that GRK2’s inhibition of the 
PI3K/Akt pathway is at least in part responsible for the inhibition of PAR-1-dependent 
NF-κB signaling by GRK2 (Figure 4-2). Parsing out which of these models of GRK2 
inhibition is correct, if not both of them, will be difficult but important. This is because 
GRK2 has been recognized as a promoter of endothelial dysfunction which seems to 
contradict our finding that GRK2 can down regulate the pro-inflammatory signals of 
PAR-1-dependent NF-κB signaling (discussed in future directions) (34,35).  
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Future Directions 
 
 1) Which GRKs are responsible for PAR-1-dependent NF-κB signaling? 
β-arrestin 1 and β-arrestin 2 are essential for PAR-1 to activate the NF-κB 
pathway. Which GRKs are responsible for the recruitment of β-arrestins to PAR-1 for 
NF-κB activation remains unknown (Figure 4-2). Addressing this question provides an 
opportunity to identify a new kinase family involved in GPCR-CBM complex signaling, 
and could reveal a pharmaceutical target that would not affect T-cell receptor-CBM 
complex recruitment. Since we ruled out GRK2 at the beginning of our siRNA screening 
(Figure 3-5), future efforts will focus on GRK5 and GRK6 as the most likely candidates to 
recruit the CBM complex to PAR-1.  
SVEC4-10 cells will be transfected with Dharmacon smartpool siRNA for 
individual GRKs and knockdown will be monitored by western blot using commercially 
available antibodies. Additionally, GRK2 family members will also be evaluated to assure 
there are no off-target effects of the siRNA. Once knockdown is achieved, effects of 
depleting each GRK on the NF-κB pathway will be initially measured by western blot for 
p-IκBα (Ser32/36) and p65 nuclear localization to assure the whole pathway is equally 
affected. To determine the effect of GRK depletion on PAR-1’s ability to recruit β-
arrestins, cells will be stimulated with thrombin and then treated with a membrane-
permeable hydrolysable protein crosslinker Dithiobis[succinimidylpropionate], after which 
PAR-1 will be immunoprecipitated and western blot will be performed to determine 
changes to β-arrestin 1 and β-arrestin 2 receptor binding (36).  
The physiological relevance of depleting the target GRKs will be assessed by 
measuring thrombin-induced monocyte adhesion to endothelial cell cultures as 
described in chapter 2. An alternative to using siRNA depletion of GRKs would be to 
carry out these experiments with kinase dead GRKs (GRK5-K215R and GRK6-K215R) 
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which inhibit GPCR β-arrestin recruitment. Due to the potentially redundant nature within 
the GRK subfamily, both members may need to be depleted to achieve maximal effect 
(37). We expect GRK5 and/or GRK6 will be responsible for PAR-1-dependent NF-κB 
signaling in the endothelium (Figure 4-2). 
 
2) What is the mechanism for GRK2-mediated down regulation of NF-κB signaling 
in the endothelium? 
We demonstrated that GRK2 acts as an inhibitor of PAR-1-dependent canonical 
NF-κB signaling through an unclear mechanism that may involve the need for PI3K/Akt 
activation (Figure 3-5) (8,17,38). It has been published that in vivo models of vascular 
injury cause an increase in GRK2 expression which contributes to endothelial 
dysfunction through inhibition of the Akt/eNOS/NO pathway, decreasing vasodilation 
(33,34,39). It was recently found that insulin-dependent Akt activation was also inhibited 
by GRK2 in an in vivo model of endothelial dysfunction [32]. This supports the theory 
that GRK2 inhibition of Akt signaling is a universal function of GRK2, unlike its role in 
GPCR desensitization (Figure 4-2). These results seem contradictory since GRK2 
inhibition of NF-κB signaling is considered to protect against endothelial dysfunction 
(Figure 4-1), while GRK2’s inhibition of Akt/eNOS/NO signaling is known to promote 
certain aspects of endothelial dysfunction. Liu et al. illustrates that the Akt inhibition due 
to GRK2 can be overcome with the expression of the constitutively active Akt mutant, 
myr.Akt (34). If GRK2 inhibition of PAR-1-dependent NF-κB signaling occurs through the 
Akt pathway (Figure 4-2), then transfecting the endothelial cells (SVEC4-10) with 
myr.Akt followed by thrombin stimulation should overcome GRK2’s inhibition. 
Phosphorylation of GSK-3, a known Akt kinase substrate, will be used to monitor Akt 
activity. If it appears that GRK2-Akt interaction is responsible for PAR-1-dependent NF-
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κB inhibition, we will use co-immunoprecipitation to confirm that GRK2 is binding to Akt 
and also test if this interaction is affected by thrombin stimulation. 
To evaluate the possible contributions of GRK2-dependent phosphorylation and 
desensitization of PAR-1, we will perform the following experiments. PAR-1 will be co-
immunoprecipitated as described in aim 1 and evaluated by western blotting for 
alterations in PAR-1’s ability to bind to β-arrestins when GRK2 is depleted as compared 
to control siRNA cells (36,40). Additionally, PAR-1 phosphorylation status will be 
measured in control and GRK2 siRNA transfected cells pre-incubated with [32P]Pi and 
then stimulated with thrombin. PAR-1 will be immunoprecipitated and alterations in 
phosphorylation due to GRK2 depletion or expression of a kinase dead GRK2 mutant 
(GRK2-KD) will be analyzed by autoradiography (34,36,40). By evaluating both GRK2’s 
effects on PAR-1-dependent NF-ĸB and Akt signaling in the same model, we should 
gain insight into the potential contribution of each mechanism in regulating PAR-1-
dependent endothelial dysfunction (Figure 4-2).  
 
3) An in vivo model of PAR-1-dependent NF-κB activation and endothelial 
dysfunction 
Vascular injury increases GRK2 expression in vivo which is a contributing factor 
to post-injury endothelial dysfunction. Decreasing GRK2 levels leads to a partial 
restoration of normal endothelial function through increased NO production (Figure 4-2). 
Also, Grk2+/- mice had a less severe endothelial dysfunction phenotype after insult 
(33,34). In contrast, we showed that increasing GRK2 protects against PAR-1-
dependent NF-κB activation, a phenomenon that should prevent certain aspects of 
endothelial dysfunction (Figure 3-5, 3-8). It should be noted that PAR-1-dependent Akt 
activation does not lead to NO production, but instead PAR-1-dependent activation of 
ROCK causes inhibitory phosphorylation of eNOS, thus causing a rapid decrease in NO 
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levels (29,41). The seemingly bipolar nature of GRK2 in endothelial dysfunction raises 
some complex questions: 1) If increasing GRK2 levels has both pro- and anti- 
endothelial dysfunction properties, which is more important in a disease state? 2) To 
what degree is PAR-1 contributing to endothelial dysfunction once GRK2 expression 
levels rise? 
In the following experiments, we will evaluate the role of PAR-1 and determine its 
pathophysiologic contributions following the initiation of endothelial dysfunction. We will 
use the well-characterized in vivo model of endothelial dysfunction induced by liver 
portal hypertension that is surgically induced by common bile duct ligation (CBDL) in 
adult male rats (34,42-44). Portal hypertension is a restriction of the blood flow through 
the portal vein due to liver injury, such as cirrhosis, causing hypertension in the portal 
vein and its branches. This model will allow us to extend our research into a new 
disease state, portal hypertension, which shares similarities with atherosclerosis, such 
as decreased vasodilation, dysfunctional endothelium, and vascular remodeling (34,45). 
Additionally, PAR-1 is relevant to this disease as the severity of human liver cirrhosis 
correlates with increasing PAR-1 expression (46).  
3a) If portal hypertension inhibits Akt signaling in vivo does this mean NF-
κB signaling is also inhibited? First, we will evaluate the level of NF-κB signaling 
induced by CBDL surgery in primary sinusoidal endothelial cells since Liu et al. 
demonstrate down regulation in Akt signaling was innate due to the surgery itself (34). 
Protocols for CBDL surgery, liver perfusion, and isolation of primary endothelial cells 
from male Sprague-Dawley will be as described by Liu et al. (34,47). Primary endothelial 
cells will be collected ten days after CBDL operation, as this has been reported to be the 
peak of injury-induced increase in GRK2 expression (34). Via western blot, we will 
gather data on downstream markers of endothelial health such as pro-inflammatory 
markers (Figure 4-2): p-IκBα (Ser32/26), p-eNOS (Thr495an inhibitor phosphorylation), p65 
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nuclear localization, CAM induction (VCAM-1, ICAM-1), and anti-inflammatory markers 
such as p-eNOS (Ser1177an activating phosphorylation), p-AKT (Ser473), and p-GSK-3 to 
compare samples from CBDL versus sham operation (4,29,34). Also, phosphorylation of 
ERK will be assessed as a negative control which, based on our in vitro data, will not 
change due to alterations in GRK2 expression. GRK2 will also be probed to make sure 
that injury has induced an increase in GRK2 expression.  
Additionally, we will compare transcription levels of pro-inflammatory cytokines 
(IL-6, IL-18) and chemokines (MCP-1, MIP-1α), CAM (VCAM-1, ICAM-1) and anti-
inflammatory cytokines (IL-10) by quantitative real-time PCR from CBDL versus sham 
operation (4). We will also monitor the transcription levels of GRK2. As part of the liver 
perfusion process, we will measure portal vein pressure as described by Rockey et al. to 
collect data on changes in vascular tone to add another measure of endothelial 
dysfunction (48). Previous studies of the role of GRK2 in endothelial dysfunction were 
narrow in scope; our experiments here will provide a more complete picture of the 
impact an increase in GRK2 has on the functioning of the endothelium (33,34). We 
predict that the increase in GRK2 levels will reduce both NF-κB activity and NO 
production in these cells. However, this reduction in NF- κB signaling may not be 
significant enough to inhibit NF- κB signaling from continuing to contribute to ongoing 
endothelial dysfunction.  
3b) Since GRK2, an inhibitor of PAR-1-dependent NF-κB signaling, is 
increased during endothelial dysfunction, does PAR-1 continue to have a role in 
the endothelial dysfunction beyond initiation? In order to evaluate the ability of 
thrombin to induce NF-κB signaling in endothelial cells that are already dysfunctional, we 
will use the method described above to isolate and culture primary sinusoidal endothelial 
cells from CBDL and sham-operation rats. Lui et al. demonstrated that these cells, even 
after four days in culture, maintained the dysfunction phenotype with inhibition of the 
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Akt/eNOS/NO signaling pathway, and had significantly increased GRK2 expression 
when compared to control cells (34). Primary endothelial cells will be grown to a 
monolayer then treated with thrombin. Protein and mRNA extracts will be collected and 
evaluated as described in question 3a. These cells can also be readily transfected with a 
GRK2 siRNA pool, challenged with thrombin, and screened for NF-κB induction as 
previously described in question 3a to confirm that GRK2 is responsible for any inhibition 
of PAR-1/NF-κB signaling. Based on our studies in immortalized endothelial cells (Figure 
3-7), we would predict an overall decrease but possibly not a complete inhibition in NF-
κB signaling in cells with elevated GRK2 expression levels. This would mean that 
increased GRK2 expression is associated with both anti- and pro- endothelial 
dysfunction influences in the cell (Figure 4-2). If so, it becomes a question of which 
GRK2-mediated signaling pathway has a stronger influence on endothelial cell 
dysfunction: CBM complex/NF-κB or Akt/NO signaling? Is PAR-1 signaling more 
important to the initial stages of endothelial dysfunction than to maintaining it? 
3c) Can PAR-1-dependent NF-κB signaling continue to contribute to 
endothelial dysfunction once GRK2 levels increase in vivo? Unlike in humans, PAR-
1 is not the receptor for platelet activation and aggregation in rats (49). This allows for 
the PAR-1-specific agonist, TRAP-6 (Figure 2-1), to be administered in vivo without 
causing clotting in the vasculature (49-52). We will exploit this difference to test PAR-1 
signaling in this in vivo endothelial dysfunction model. The adult male rats will receive 
CBDL or sham surgery and be allowed to recover for ten days by which time Liu et al. 
reported that the increase in GRK2 expression will have peaked and the portal vein 
endothelium will be dysfunctional. At this point we will subcutaneously implant osmotic 
minipumps (Alzet) filled with either saline (negative control) or TRAP-6 peptide diluted in 
saline. This method has previously been shown to be able to successfully deliver peptide 
hormones for GPCR activation to the liver after CBDL surgery (53,54). These will 
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continuously release TRAP-6 for two weeks before sinusoidal endothelial cells are 
isolated and protein and mRNA extracts are made and evaluated as described in 
question 3a. Any reduction in PAR-1 activity in the dysfunctional rat endothelium can be 
confirmed to be caused by increased GRK2 expression by using one of these methods 
of in vivo GRK2 inhibition. Taguchi et al. used a specific chemical inhibitor of GRK2 
kinase activity (βARK1 inhibitor) to restore aortic endothelial function in male ob/ob 
C57BL/6J mice, which we could administer via minipump along with TRAP-6 or saline 
(33,55). Additionally, adenovirus-expressing GRK2 shRNA could be injected into the 
femoral vein for successful knock down in the liver [32, 33, 51]. Any comparison 
between treatment groups will be carried out as described in question 3a. These 
experiments, along with our previous data, are likely to show that PAR-1-dependent NF-
κB signaling is most robust in the early steps of endothelial dysfunction but is tuned 
down as the disease progresses. This will be due to GRK2’s ability to inhibit Akt activity 
and this mechanism may very well apply to multiple receptors’ abilities to activate NF-κB 
signaling in the context of established endothelial dysfunction (Figure 4-2).  
 
Summary of chapter 
In this chapter, I have outlined a series of experiments designed to explore the 
critical questions that come out of the work presented in this thesis and to take strides to 
increase the impact of our discoveries. Our findings that β-arrestins are indispensable for 
PAR-1-dependent NF-κB signaling raise a host of new questions which bring to light two 
new families of proteins, β-arrestins and GRKs, that are important for CBM complex-
dependent NF-κB activity.  
To determine which GRK is essential for recruiting the CBM complex to the 
receptor for NF-κB activation, we propose using siRNA knockdown to screen each GRK 
for its impact on PAR-1 signaling. To this end, we began by testing the role of GRK2, but 
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surprisingly we established that GRK2 acts as an inhibitor of PAR-1-dependent NF-κB 
signaling. The most probable mechanism by which GRK2 inhibits this response is 
through either promoting internalization/desensitization of PAR-1 receptors and/or 
causing direct inhibition of Akt activity. This chapter describes several experimental 
approaches to distinguish these two possibilities. Lastly, I propose here a series of in 
vivo experiments designed to explore the interplay of GRK2 and PAR-1-dependent NF-
κB signaling in the initiation and progression of endothelial dysfunction, with a focus on 
the efficacy of GRK2 as a therapeutic target. Thus far, GRK2 has been described as a 
mediator of endothelial dysfunction due to its ability to inhibit the Akt/eNOS/NO pathway. 
Based on this observation, it has been suggested that blocking GRK2 activity may be an 
effective approach for the treatment of diseases in which endothelial dysfunction plays a 
prominent role. However, our in vitro findings that inhibition of GRK2 increases two 
important endothelial dysfunction markers, NF-κB activity and VCAM-1 expression, call 
this notion into question so that GRK2 inhibition as a treatment approach may be 
seriously flawed. The experiments outlined in this chapter should establish which is the 
more influential function of GRK2: inhibition of NO production or NF-κB activity. This will 
clarify the potentially paradoxical actions of GRK2 in vascular disease, leading to a 
better understanding of endothelial dysfunction and the regulation of PAR-1-dependent 
NF-κB signaling (Figure 4-2).  
 
Summary of thesis 
In this thesis, we provide new insights into the complex regulation of GPCR-
dependent cell signaling. Our work establishes that PAR-1’s recruitment of the CBM 
complex causes the activation of the potent pro-inflammatory NF-κB signaling pathway 
(Figure 2-2). The CBM complex is necessary for PAR-1’s ability to induce the expression 
of NF-κB-dependent proteins important for endothelial dysfunction, such as VCAM-1 for 
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monocyte/endothelial cell adhesion (Figure 2-7, 2-8). We next explored the role of β-
arrestins in PAR-1-dependent NF-κB activity. While β-arrestin 2 appears to recruit the 
CBM complex to the PAR-1 receptor, we found that β-arrestin 1 is also required for 
effective PAR-1-dependent NF-κB activation, unlike what has been shown for the LPA 
receptor (Figure 3-1). The requirement for β-arrestin 1 is likely due to its ability to 
mediate PAR-1-dependent ROCK and Akt activation, which are likely involved in IKK 
complex phosphorylation (Figure 2-4, 2-5, 3-3, 3-4). Lastly, while trying to discover the 
GRK responsible for the β-arrestin-dependent recruitment of the CBM complex to PAR-
1, we discovered that GRK2 is an inhibitor of PAR-1-mediated NF-κB signaling, possibly 
due to GRK2’s inhibition of Akt activity (Figure 3-5). This finding, along with previously 
published work on GRK2, suggests that GRK2 has conflicting effects on endothelial 
dysfunction, raising the question of which effect is more influential in endothelial biology 
(Figure 4-2). We believe that this research sheds new light on the poorly understood 
mechanism of NF-κB signaling by many, but possibly not all, GPCRs and we hope this 
will prove useful for the future development of treatments to combat GPCR-influenced 
pro-inflammatory disease. 
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Figure 4-1. The CBM complex is at the crossroads of GPCR-dependent endothelial 
dysfunction. We have shown that both AGTR1 and PAR-1 use the CBM complex to 
induce endothelial dysfunction by activation of NF-κB signaling (8,9). See text for more 
detail.  
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Figure 4-2. Mechanisms of regulation of PAR-1-dependent NF-κB signaling. The 
pathways on the left are involved in regulating PAR-1-dependent NF-κB signaling. On 
the right is the reported mechanism of GRK2 in inhibiting vasodilation (33,34). Others 
have reported that NO inhibits NF-κB signaling (30,31,56). See text for more detail.  
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